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1.1 Stereotactic radiotherapy
Cancer is one of the leading causes of death in the world. Next to surgery and chemotherapy,
radiotherapy is one of the most used treatment modalities for cancer. About 50% of the
patients with cancer will be treated with radiotherapy during the management of their disease.
In radiotherapy, ionizing radiation is used to kill proliferating tumor cells. As an un-
wanted (but sometimes unavoidable) side-effect, delivery of ionizing radiation to the patient
may also lead to damage to healthy tissues. Generally, the total dose is delivered in a number
of daily fractions. In between fractions, the healthy tissues can often more effectively repair
part of the damage than tumors. Hence, the cumulative damage to tumor tissue is higher
than for normal tissue when exposed to the same total dose in a large number of fractions.
For most tumors and healthy tissues, this differential repair effect is enhanced with higher
numbers of fractions.
Apart from fractionation, the balance between eradication of tumor cells and treatment
related toxicity is also dependent on the accuracy of daily tumor localization at the treatment
unit, and on the quality of the delivered dose distribution, preferentially with low volumes
of critical organs irradiated to high doses. In external beam radiotherapy (EBRT), the tu-
mor dose is delivered with a linear accelerator, using a set of treatment beams that enter the
patient from different directions. For each direction, the beam is shaped according to the
projection of the tumor. Beam shaping is performed with a multi-leaf collimator (MLC). In
3D conformal radiotherapy (3D-CRT), the applied beam profiles are flat or wedge shaped.
In intensity modulated radiotherapy (IMRT) the beam intensity profiles are customized to
optimally focus the radiation on the tumor. EBRT dose distributions are usually designed
by a dosimetrist, using treatment planning software and a planning CT-scan of the patient.
During treatment planning, all treatment parameters, such as the number of beams, the beam
directions, intensity modulation, and beam shapes are defined.
In contrast to more conventional 3D-CRT or IMRT, for stereotactic radiotherapy the
total dose is delivered in one or a small number of fractions with a high dose per fraction,
resulting in a much higher biological effective dose to the tumor. For example, a fractionation
schedule consisting of 3 fractions of 20 Gy, as often applied in stereotactic lung treatments,
has the same biological effect as a dose of 150 Gy delivered in fractions of 2 Gy. In the latter
case, 75 fractions are needed, which is generally considered too high. Therefore, stereotactic
radiotherapy is well suited for treatment of tumors that are highly insensitive to radiation.
Another characteristic of stereotactic treatments is the high dosimetrical and geometri-
cal precision. Because of the low number of fractions, the differential inter-fraction repair
effect as discussed above may be much reduced in stereotactic treatments. The higher chance
on toxicity related to the applied low number of fractions is counteracted by more focused
dose distributions, and the increment in geometrical and dosimetrical precision, which allows
for smaller target volumes yielding smaller volumes of normal tissue receiving a high dose.
The focused dose distributions for stereotactic radiotherapy are characterized by a high con-
formality of the dose distribution to the target volume, a high dose fall-off between target
volume and normal tissue, and minimization of the dose to organ at risk (OAR), which is
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accomplished by advanced dose delivery techniques and optimization of the planned dose
distribution.
Initially, stereotactic radiotherapy was developed for tumors inside the skull (intra-
cranial stereotactic radiotherapy). Later on, the technique has been copied for treatment of
extra-cranial tumors (stereotactic body radiation therapy, SBRT[1,2].
1.2 Outline of this thesis
This thesis discusses several techniques for more focused stereotactic irradiation of intra-
cranial (chapter 2) and extra-cranial (liver) tumors (chapters 3 to 7). Chapter 2 investigates
the advantages and feasibility of partial cone blocking in (static) arc therapy for small intra-
cranial lesions.
Chapter 3 describes adaptations to the in-house developed beam direction and beam
weight optimization algorithm (’Cycle’) for SBRT. Important extensions of Cycle for SBRT
are the inclusion of beam shape optimization, and the inclusion of non-coplanar beam ori-
entations (i.e., outside the axial plane of the patient). In chapters 3 and 6, it is investigated
whether automated non-coplanar beam direction optimization with the extended Cycle algo-
rithm improves the therapeutic ratio for SBRT of liver patients treated with 3D-CRT or IMRT,
respectively.
In chapter 4, Cycle is used to compare liver SBRT based on dose prescription at the sur-
rounding 65% isodose with dose prescription at 80%. Both strategies are often encountered
in literature[1,3]. In chapter 5, using Cycle, treatment plans are generated with a maximized
generalized equivalent uniform dose (gEUD) for the PTV, and compared with the strategies
using 65% or 80% dose prescription.
Clinical introduction of improved treatment technologies, such as daily 4D-CT image
guidance for SBRT of liver tumors, may allow the use of smaller CTV-PTV margins. In
chapter 7, the effect of smaller margins on the treatment planning is investigated.
Bibliography
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Abstract
Purpose:
Stereotactic arc treatment of small intra-cranial tumors is usually performed with arcs colli-
mated by circular cones, resulting in treatment volumes which are basically spherical. For
non-spherical lesions this results in a sub-optimal dose distribution. Multiple isocenters may
improve the dose conformity for these lesions, at the cost of large overdosages in the target
volume. To achieve improved dose conformity as well as dose homogeneity, the linac jaws
(with a minimum distance of 1.0 cm to the central beam axis) can routinely be used to block
part of the circular beams. The purpose of this study was to investigate the feasibility of
blocking cones with diameters as small as 1.0 cm and a minimum distance between the jaw
and the central beam axis of 0.3 cm.
Materials and methods:
First, the reproducibility in jaw positioning and resulting dose delivery on the treatment unit
were assessed. Second, the accuracy of the TPS dose calculation for these small fields was
established. Finally, clinically applied treatment plans using non-blocked cones were com-
pared with plans using the partially blocked cones for several treatment sites.
Results and conclusion:
The reproducibility in dose delivery on our Varian Clinac 2300 C/D machines on the central
beam axis is 0.8% (1 SD). The accuracy of the TPS dose calculation algorithm is critically
dependent on the used fits for the penumbra and the phantom scatter. The average deviation
of calculated from measured dose on the central beam axis is -1.0%±1.4% (1 SD), which is
clinically acceptable. Partial cone blocking results in improved dose distributions for elon-
gated tumors, such as vestibular schwannoma and uveal melanoma. Multiple isocenters may
be avoided. The technique is easy to implement and requires no additional workload.
Chapter 2 17
2.1 Introduction
Small intra-cranial tumors are often treated with linac based stereotactic radiosurgery (SRS)
and radiotherapy (SRT)[1] using multiple arcs with circular collimators, resulting in treatment
volumes which are basically spherical. However, in general the shape of the lesion (GTV)
and the Planning Target Volume (PTV) are non-spherical.
Therefore, to improve the dose conformity to the target volume, arcs with multiple
isocenters, each using a smaller cone size for collimation, are often applied clinically. A
disadvantage of this technique is the increase in dose inhomogeneity in regions where arcs
with different isocenters overlap. Large overdosages in the PTV, and perhaps in small areas
of normal tissue, will be present [2]. Other disadvantages of using multiple isocenters are the
geometrical set-up inaccuracy introduced when changing from one isocenter to the other, and
the increase in treatment time.
By partially blocking the circular collimator opening with the collimator jaws, the dose
distribution becomes more elliptical [1]. This solution is routinely available in the Radion-
ics XKnife software∗ for cones having a diameter of 2.0 cm and larger, and jaw positions
equal to or larger than 1.0 cm from the central beam axis. Bellerive et al. [1] compared dose
distributions for arc treatments with circular cones using either single or multiple isocenters
with arc treatments using partially blocked cones. They concluded that by using partially
blocked cones for lesions greater than 3.0 cm in maximum extent, the dose homogeneity
in the target volume was increased, while the dose delivered to healthy tissue was reduced.
Hacker et al. [3] compared single isocenter stereotactic arc treatment plans using cones, four
independent static jaws (i.e., without a cone) and an ’ideal’ collimator.
The latter collimator adjusts its shape continuously in such a way, that its projection in
the beams eye view (BEV) always matches the projection of the PTV in the BEV. For tumors
with a maximum extent larger than 3.5 cm, the dose conformity to the target volume using
four independent jaws was much better than using cones. The mean volume of involved nor-
mal tissue at the prescription dose was reduced by 57% if the collimation was performed
either with four independent jaws or with an ’ideal’ collimator instead of a cone. For lower
doses, the volume of involved normal tissue was further reduced by using the ’ideal’ col-
limator instead of the jaws. In a modeling study, Nedzi et al [4] compared several dynamic
(i.e., the collimator shape changes during the arc) field shaping devices, including both an
’ideal’ collimator and a cone dynamically blocked with the jaws, with a conventional cone,
for tumors with a maximum dimension between 2.0 and 4.2 cm. The treatment volume ratio
(TVR; target volume divided by the treatment volume at the prescription dose) was increased
from 37% for a conventional cone to 44% for the dynamic jaw collimator and to 55% for the
’ideal’ collimator.
Miniature Multileaf Collimators (MMLC), having leaf widths of 3-5 mm at isocen-
ter [2,5,6] can also be used for the stereotactic treatment of intra-cranial lesions, either using
multiple static beams[2,5], using dynamic arcs [7] or using static intensity modulated beams[5,7]
Their usefulness in improving target conformity has especially been demonstrated for lesions
∗Radionics, Thyco Healthcare, Burlington, MA
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> 3 cm. Techniques using dynamic arcs and IMRT beams are more complicated and require
a more extensive quality assurance than techniques using cones.
In this paper, we investigate the feasibility of using partially blocked cones with diam-
eters as small as 1.0 cm, and with a minimum jaw position of 0.3 cm from the central beam
axis, to improve target conformity for small elongated tumor volumes. Because the fields are
very small, a small deviation in jaw position may introduce considerable deviations in the de-
livered absolute dose value, and the total high dose volume. Therefore, the reproducibility in
jaw positioning and resulting dose delivery of these small fields was investigated. Second, the
accuracy of the treatment planning system (TPS) dose calculation was investigated for these
small fieldsizes. The calculations of the TPS were compared with absolute measured dose
values on the central beam axis, and with measured profiles. Finally, several clinical treat-
ment plans were compared with plans using partially blocked cones. The presented tumor
sites are a vestibular schwannoma and a uveal melanoma.
2.2 Materials and methods
2.2.1 Treatment Unit
In our institution, stereotactic arc treatments are performed using the 6 MV beam of a Varian
Clinac 2300 C/D† accelerator. Circular collimators (Radionics) (cones) are available with
diameters ranging from 0.5 cm to 5.0 cm at isocenter, with an increment in diameter of
0.25 cm. Partial blocking of the cones is performed using the four independent jaws of the
accelerator. With these jaws, any rectangular field can be set, with a resolution in jaw position
of 1.0 mm. Any jaw that is not used to block part of the cone is set at a distance of 3.0 cm
from the central beam axis.
2.2.2 Treatment Planning System
The XKnife TPS is used for treatment planning[8] The dose, D, for a partially blocked field
in a point x,y,z is calculated using the following algorithm:
D(d,s jaw,snet ,x,y,z) =M×Sc(s jaw)×Sp(snet)
×TMR(d,snet)×Φ(x0,y0)× SAD
2
(SAD− z)2
with Φ(x0,y0) = OAR(x0,y0)×Px1 ×Px2 ×Py1 ×Py2
(2.1)
The factorM relates the reference field in XKnife to the linac calibration field. Sc is the
collimator scatter factor as a function of the equivalent square field width, s jaw, of the jaw
field (the cone is ignored in the calculation of s jaw because its influence on the collimator
scatter can be neglected). Sp is the phantom scatter factor as a function of the equivalent
square field width, snet , of the field shaped by the jaws and the cones at the patient skin. The
Tissue Maximum Ratio, TMR, is a function of snet and the depth in the patient, d. Φ accounts
for the off-axis dose distribution by multiplication of the OAR, the off-axis ratio measured
†Varian Assoc., Palo Alto, CA
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for the cone, with the product of the jaw penumbra factors, Px1 , Px2 , Py1 , Py2
[9]. x0 and y0 are
the lateral coordinates x,y scaled to the isocenter plane. SAD is the Source to Axis Distance
and z is the coordinate along the central beam axis in the direction of the linac isocenter.
Measured Sc and Sp data are fitted to a simple function with the variable s as the width
of the equivalent square field.
Sc,p(s) = ac,p−bc,p exp(−cc,ps) (2.2)
The algorithm (Eq. 2.1) uses these fitted functions to determine Sc and Sp by substituting
their corresponding equivalent square field width.
Penumbra Factor
Fits to the penumbras of the measured inline and crossline profiles for a 4 cm square field are
required to determine the penumbra factors, Px1 , Px2 , Py1 , Py2 . The penumbra of the actual
profile has to be fitted to the following equation:
P=
{
1−0.5exp(−ain|x|) for x< 0 (inside the field)
T0+(0.5−T0)exp(−aout |x|) for x> 0 (outside the field)
(2.3)
T0 is the jaw transmission factor, ain and aout are the penumbra fit parameters, respec-
tively inside and outside the field. The 50% value of each penumbra factor coincides with the
edge (at x= 0) of the corresponding jaw.
For jaw settings smaller than 1.0 cm from the central beam axis the influence of the pe-
numbra on the central axis dose increases. Because the accuracy of the algorithm is assessed
for these jaw settings, it is crucial that the correct penumbra fit is applied. The penumbra
profile was determined using a diode with an effective detection diameter of 2.5 mm. This
measured profile is a convolution of the actual profile with the response kernel of the diode
detector [10]. The smoothing effect of the diode on the measured profile was eliminated by
fitting the convolution of the penumbra factor function (Eq. 2.3) with the gaussian response
kernel of the diode detector [11] to the measured profile using the least squares method. The
parameters ain, aout and T0 resulting from the best fit, determine the deconvolved penumbra
fit. The deconvolved penumbra fit results in a reduction of 0.6 mm of the 20%/80% penumbra
width, from 3.1 mm to 2.5 mm (Fig. 2.1), which agrees with previous investigations[11,12]
where a reduction of 0.5 mm in the 20%/80% penumbra was observed using a diode with a
diameter of the sensitive volume of 2.5 mm. As shown in Fig. 2.1, for jaw settings closer
than 0.8 cm to the central beam axis, it is important to apply a deconvolution to the measured
profile, otherwise large inaccuracies in calculated dose values on the central beam axis can
be present: e.g., at 3 mm from the field edge, the deconvolved fit is about 3% higher than the
measured fit.
Phantom Scatter
Sp is measured directly, using a constant linac collimator opening of 6.0× 6.0 cm2 (resulting
in a constant collimator scatter, Sc), and only changing the cone diameter (Fig. 2.2). These
measured Sp values are fit to the function in Eq. 2.2, using the relation s = 0.891 · d for the
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Figure 2.1: Penumbra fits based on a measured profile for a 4 × 4 cm2 field; including the
spatial smearing of the detector (dashed line), and after applying a deconvolution to eliminate
the spatial influence of the diode detector (solid line), and the relative difference between both
fits (dash-dotted line).
equivalent square field width of a circular field[13] where d is the diameter of the circular
field.
For circular fields with a diameter less than 2.0 cm, the dose on the central beam axis
is highly influenced by lateral electron disequilibrium[14]. Therefore the phantom scatter
cannot be measured directly for these fields. Our investigations demonstrate that a fit based
on measurements for field diameters of 2.0 cm and larger corresponded very well to the data
of Bja¨rngard et al. [14], who determined the phantom scatter as a function of field diameter
for a clinical 6 MV beam using Monte Carlo simulations (Fig. 2.2). In the TPS algorithm
(Eq. 2.1), the electron disequilibrium on the central beam axis caused by small jaw settings
is taken into account by the penumbra factors (Eq. 2.3).
2.2.3 Measurements and calculations
Reproducibility in jaw positioning and dose delivery
The reproducibility in jaw positioning and resulting dose delivery was determined for a set
of 15 square and rectangular fields. The minimum distance of each jaw to the central beam
axis was 0.3 cm. Realized jaw positions were measured using the light field of the linac, as
well as using X-ray films (Kodak X-Omat V). The dose measurements were performed at the
isocenter at the depth of dose maximum with a diode in a water phantom‡ To determine the
short term reproducibility, the set of fields was set up five times in random order and the jaw
‡Wellho¨fer-Scanditronix, IBA, Husbyborg, Uppsala, Sweden
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Figure 2.2: Central axis ionization measurements (triangles) at depth=dmax for cones with the
collimator jaws fixed at 6.0 × 6.0 cm2 plotted against the equivalent square field width, s. The
measurements are normalized to the measurement for a 6.0× 6.0 cm2 open field. The corrected
values (solid line) based on a fit to the measured data for cone diameters of 2.0 cm and larger,
and the Monte Carlo derived Sp data by Bja¨rngard et al. [14] (circles) are plotted. The equivalent
square field width, s, is related to the diameter, d, of the cones by s= 0.891 ·d [13].
positions as well as the dose delivery were measured. To check the long term stability, the
measurements were repeated during a period of 2 months.
Accuracy of the dose calculation algorithm
Clinically, the TPS dose calculation algorithm is used for blocked cones with a minimum dis-
tance between the jaw edge and the central beam axis of 1.0 cm. To investigate the accuracy
of the dose calculations for jaw positions closer to the central beam axis, with a minimum dis-
tance of 0.3 cm, absolute and relative dose calculations were compared with measurements.
First, the absolute dose at the central beam axis at 1.5 cm depth was measured to assess
the accuracy of the absolute dose calculations for a set of 60 symmetric rectangular fields
with dimensions between 0.6 × 0.6 cm2 and 6.0 × 6.0 cm2. In addition, the absolute dose
at the central beam axis was measured for a set of 290 fields shaped by partially blocked
cones (with diameters of 1.0, 1.5, 2.0, 3.0 and 4.0 cm). Symmetric and asymmetric jaw
settings were applied. The absolute dose measurements for the partially blocked cones were
performed at four depths: 1.5, 5, 10 and 15 cm. The measurements were normalized to the
value measured at dmax( = 1.5 cm ) for a 10 × 10 cm2 field at a source to skin distance of 100
cm. This field is the calibration field of the linac, for which 1 monitor unit equals 1 cGy.
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Second, measured and calculated profiles in the X and Y direction at different depths
(1.5–15 cm) were compared for a set of partially blocked fields with cone diameters ranging
from 1.0 to 3.0 cm and with varying jaw settings. The isocenter was positioned either at 1.5
or 5.0 cm depth. All measurements were performed using the same shielded diode and water
phantom used to acquire the input data for the TPS.
2.3 Results and discussion
2.3.1 Reproducibility
Our investigations demonstrate that the short and long term reproducibility in jaw positioning
of our Varian 2300 C/D machines is 0.3 mm (1 SD), independent of fieldsize, gantry angle
and collimator angle. For rectangular fields larger than 0.8× 0.8 cm2, the short and long term
dosimetric reproducibility was within 0.4% (1 SD). For fields with a width of 0.6 cm, the re-
producibility in delivered dose was within 0.8% (1 SD). Using the dose calculation algorithm
(Eq. 2.1), the variation in dose delivery resulting from the variation in jaw positioning was
estimated, and turned out to be of the same order as the actually measured dose reproducibil-
ity. It is important to note that in our experience the actual reproducibility in jaw positioning
is much better than 1.0 mm which is specified by the Varian Acceptance Procedure. These
results indicate that the Varian 2300 C/D machine is suitable for accurate and reproducible
dose delivery using very small fields [15] with a minimum fieldside of 6 mm.
Cone Diameter
(cm) d (cm) X (%) S (%) Max (%)
1.0 1.5 and 10 1.0 1.9 4.3
1.5 1.5 0.3 1.3 2.3
1.5 10.0 -0.1 1.2 2.2
2.0 1.5 -0.8 1.1 2.9
2.0 5.0 -1.5 0.8 2.7
2.0 10.0 -1.8 0.9 3.8
2.0 15.0 -2.2 0.9 3.8
3.0 1.5 -1.2 1.0 2.9
3.0 10.0 -2.2 1.5 3.5
4.0 1.5 -1.3 0.6 2.4
all cones all depths -1.0 1.4 4.3
Table 2.1: Average deviation, X, of calculated from measured dose on the central beam axis,
spread, S, around this average, given as one standard deviation, and maximum deviation, Max,
for a large set of partially blocked fields, for several cone diameters and depths. The results for
the 1.0 cm cone are combined for both depths, because the number of partially blocked fields
that can be set up is small for this cone.
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Figure 2.3: Ratio of calculated and measured dose on the central axis, for partially blocked
cones (open circles), and symmetric rectangular fields at depth=1.5 cm (squares). For symmet-
ric rectangular fields calculations were also performed using the non-deconvolved penumbra
fit (triangles), and using the Sp fit, based on measured data, that are not corrected for electron
disequilibrium, at depth=1.5 cm (diamonds).
(a) (b)
Figure 2.4: Profiles for a partially blocked cone at different depths (1.5, 3.0, 5.0, 7.5 and 10
cm) in (a) the X-direction and (b) the Y-direction, for a 3.0 cm diameter cone, blocked with the
collimator jaws X1 at 0.4 cm, X2 at 0.6 cm and Y2 at 1.0 cm from the central beam axis.
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2.3.2 Dose calculation accuracy of the treatment planning system
Dose calculation on the central beam axis
Measurements and calculations were compared for partially blocked fields with diameters
ranging from 1 to 4 cm, at 1.5, 5.0, 10 and 15 cm depth. Many asymmetric jaw positions
were investigated. Using the Sp fit corrected for electron disequilibrium, and the decon-
volved penumbra fit, the average deviation of the calculated from the measured central axis
dose for the complete set (for all depths and cone diameters) of partially blocked fields was
-1.0%±1.4% (1 SD), see Fig. 2.3. The deviations for different cone diameters and depths are
summarized in Table 2.1. For the set of rectangular fields (i.e. without cone) the accuracy of
the calculated central axis dose at a depth of 1.5 cm was -1.2%±0.6% (1 SD), see Fig. 2.3.
The importance of using the deconvolved penumbra fit is demonstrated in Figs. 2.1
and 2.3. Using the measured non-deconvolved penumbra fit, the calculations indicate an
increasing deviation from measurements with decreasing field size. In the algorithm, the
penumbra factors of four jaws are multiplied, which explains the 4 × 3% = 12% difference
in deviation for a 0.6× 0.6 cm2 field, when the non-deconvolved fit is used in the calculation
(Fig. 2.1). Therefore the deconvolved fit has been demonstrated to provide a superior fit.
As shown in Figs. 2.2 and 2.3, it is also important to use the correct Sp fit, where
the influence of electron disequilibrium is eliminated. If the actual measured data for field
diameters smaller than 2.0 cm would have been used to determine the Sp fit, the penumbra
influence would have been taken into account twice (by the Sp and the penumbra factor),
resulting in very large deviations of the calculated from the measured dose.
Relative dose calculations
Examples of measured and calculated profiles are shown in Figs. 2.4 (three jaws are used to
block the cones) and 2.5 (only the X-jaws are used to block the cone). In these examples, the
isocenter is situated at 1.5 cm depth (Fig. 2.4), and at 5 cm (Fig. 2.5). The normalization
point is situated on the central beam axis at depth=1.5 cm, where the measured profiles are
normalized at 100%, and the calculated dose is 100% multiplied by the ratio between the
calculated and the measured absolute dose. In this way, the absolute dose deviation is given
for all positions.
In the shown examples as well as in all other investigated situations, the geometrical
deviation in penumbra position is less than 1.0 mm on the sides that are blocked by a jaw.
On the sides that are not blocked by one of the jaws, the maximum geometrical deviation in
penumbra position is 1.5 mm. The sides that are blocked by the jaws show a deviation in
absolute dose of 2% for all off-axis positions. The largest dose deviations are observed at the
sides that are not blocked by the jaws (Y1 in Fig. 2.4(b), and Y1 and Y2 in Fig. 2.5(b)). The
maximum deviation between the calculated and measured dose was 5%.
The 5% deviation in absolute dose occurs for off-axis positions at larger depth (7.5-15
cm) on the profile parallel to the jaw edge. This is explained by the following: with decreasing
field width normal to the profile direction, the shape of the profile becomes more flat (Fig.
2.6(a)). Compared to the open cone, the reduction in dose due to electron disequilibrium is
higher on the central beam axis (point C, Fig. 2.6(b)) than at off-axis positions (e.g. point P),
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because the latter were already closer to the field edge. The algorithm uses the OAR for an
open cone, and does not correct for this flattening effect, which results in larger deviations
from the actual measured data. For a clinical treatment plan, the largest deviation of the sum
of all arcs will be much smaller. Therefore the dose calculation accuracy for these small fields
is sufficient for clinical use.
2.3.3 Comparison of clinical treatment plans
Case 1: Vestibular Schwannoma
In our institute, vestibular schwannomas are treated either with stereotactic radiosurgery or
with stereotactic radiotherapy. Most schwannomas have an elongated shape, so multiple
isocenters often have to be applied. With stereotactic radiosurgery the target receives a dose of
at least 12 Gy in a single fraction. Critical structures located close to this benign lesion are the
brain stem and the trigeminal nerve. The maximum delivered dose to these structures should
be below 10 Gy and 8 Gy, respectively. Moreover, the vestibulocochlear and facial nerves are
located inside the target volume. To preserve the function of these nerves, high overdosages
(larger than 15 Gy) should be avoided. Typically, in treatment plans with multiple isocenters
the maximum dose is 150% of the prescription dose; in our case 18 Gy. If patients have
functional hearing, fractionated stereotactic radiotherapy is applied, using 12 fractions of 2.8
Gy.
For the presented vestibular schwannoma patient, the original plan consisted of two
isocenters, with a 1.5 cm cone and a 0.75 cm cone. For the plan that uses partially blocked
cones, one isocenter was applied using a 2 cm partially blocked cone. The original plan
resulted in a large dose inhomogeneity in the PTV, up to 175% of the prescribed dose (Fig.
2.7). Because the patient had functional hearing, he was originally treated with fractionated
stereotactic radiotherapy with 12 fractions of 2.8 Gy. For comparison purposes the dose
volume histograms for the original plan are displayed (Fig. 2.7) with a normalization of
(a) (b)
Figure 2.5: Profiles for a partially blocked cone at different depths (1.5, 5.0, 10 and 15 cm):
in (a) the X-direction and (b) the Y-direction, for a 2.0 cm diameter cone, blocked with the
collimator jaws X1 at 0.3 cm and X2 at 0.3 cm from the central beam axis.
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Figure 2.6: (a) Profiles in the Y-direction for a 2 cm cone, normalized to 100% at the central
beam axis, with different jaw settings in the X-direction. (b) Diagram of the situation for the
profile measurements in (a). The profiles are measured along the line PC.
12 Gy to the prescription isodose. Because one isocenter could be applied in the partially
blocked plan, the overdosage in the PTV was reduced from 21 Gy to 15 Gy. The maximum
dose in the trigeminal nerve was reduced by 1.3 Gy, from 6.5 Gy to 5.2 Gy. The small part
of the brain stem that receives a high dose is reduced in the plan that uses the partial blocked
cone. PITV (the ratio between the volume covered by the prescription isodose contour and
the target volume) was almost the same for both plans; 2.67 for the original plan and 2.73 for
plan that uses partially blocked cones. Thus the dose inhomogeneity was largely improved,
without a loss in conformity. As a result of partial cone blocking, it would have been possible
to treat this patient with one fraction of 12 Gy instead of 12 fractions of 2.8 Gy.
Case 2: Uveal Melanoma
In our institution, uveal melanoma are irradiated to a total dose of 50 Gy in 5 fractions. Im-
portant critical structures are the optic nerve and the ciliary body. Our dose limits per fraction
are 4 Gy and 2.5 Gy, respectively. In addition to the stereotactic frame for the head fixation,
a non-invasive eye fixation camera system is used[16] comparable to the system described by
Dieckman et al. [17] for the immobilization of the eye. The original plan consisted of two
isocenters with a 1 cm cone and a 1.25 cm cone. For the new plan, one isocenter with a
2 cm partially blocked cone was applied (Fig. 2.8 ). The conformity for the new plan was
increased; the PITV could be reduced from 2.09 to 1.43. Furthermore the dose to the cil-
iary body was reduced; in the new plan the volume of the ciliary body receiving the dose
limit was reduced by 30%. Therefore the probability of neo-vascular glaucoma is reduced.
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Figure 2.7: Dose volume histograms of two different plans for a vestibular schwannoma: the
original plan with two isocenters (solid lines), and the improved plan with one isocenter using
a partially blocked cone (dashed lines).
The increase in conformity is also illustrated by Fig. 2.9, which shows the dose distribution
in three perpendicular slices through the isocenter. For the partially blocked cone plan, the
PTV is encompassed more tightly by the prescribed isodose (10 Gy). Moreover, the low dose
volume (e.g. 2 Gy) is reduced considerably.
Recently, other improved treatment techniques for uveal melanoma have been inves-
tigated and described. George et al. [7] compared conventional arc treatment with static
MMLC fields, intensity modulated MMLC fields, and dynamic arcs. In the latter situation,
the MMLC leaves move in a continuous fashion, conforming the BEV projection of the tar-
get at every angle along the path of the arc. Using dynamic arc treatments, the high dose
homogeneity and conformity to the target of the static MMLC fields are combined with the
low dose to all healthy tissue of the arc treatment. The MMLC-based techniques result in an
increase in dose conformity. Compared with the static MMLC technique, the conventional
arc and the dynamic arc technique have the advantage of dose distributions with a steeper
dose gradient. Compared with the described techniques[7], partially blocked cones will result
in comparable improved conformity. The dose distributions will have steeper dose gradients
compared to static MMLC fields. The technique is less complicated and verification is less
time-consuming than dynamic arc or IMRT techniques.
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Figure 2.8: Dose volume histograms of two different plans for a uveal melanoma: the original
plan with two isocenters (solid lines), and the improved plan with one isocenter using a partially
blocked cone (dashed lines).
2.4 Conclusion
Partial blocking of cones with diameters as small as 1.0 cm is an effective way of improving
the dose homogeneity and target conformity for small (elongated) intra-cranial lesions. The
reproducibility of both the jaw positioning (< 0.3 mm, 1 SD) and the dose delivery (< 0.8%,
1 SD for fields with at least one side equal to 6 mm and < 0.4%, 1 SD for larger fields) is
sufficient for clinical use. The dose calculation accuracy of the simple algorithm[8,9] applied
in the XKnife software is sufficient for small partially blocked fields with a minimum dis-
tance between the jaws and the central beam axis of 0.3 cm. Essential in the dose calculation
accuracy are (1) a correct phantom scatter fit, using a correction for increasing electron dis-
equilibrium for field sides smaller than 2.0 cm, and (2) a penumbra fit deconvolved for the
spatial extent of the detector used.
The absolute dose calculation on the central beam axis for the partially blocked cones
showed an accuracy of -1.0%± 1.4% (1 SD) for a large set of fields. The relative dose calcu-
lation showed dose off-axis deviations with a maximum of 5%, and a maximum geometrical
deviation of 1.5 mm. In most cases, the agreement is within 2% or 1 mm. These accuracies
are sufficient to use this algorithm clinically for partially blocked cones with a minimum jaw
setting of 0.3 cm, once the mechanical properties of the user’s treatment machine are verified.
Clinical treatment plans for small elongated lesions, such as vestibular schwannoma and
uveal melanoma can be improved considerably by partially cone blocking. Single isocenter
Chapter 2 29
200
200
200
800
800
1000
1200
1800
Eye
Cilliary Body
PTV
(a)
200
200
200
800
1000
1200
Eye
Cilliary Body
PTV
(b)
1200
200
200
200
200
800
800
1000
1800
Eye
PTV
(c)
1200
200
200
200
800
800
1000
Eye
PTV
(d)
Figure 2.9: Cont’d
30 Chapter 2
1000
200
200
200
800
800
1200
1800
Optic
Nerve
Eye
Ciliary
Body
PTV
(e)
200
200
800
1200
1000
Optic
Nerve
Eye
Ciliary
Body
PTV
(f)
Figure 2.9: Isodose lines for the non-blocked (a, c and e) and the partially blocked plan (b,
d and f) for the uveal melanoma case in the axial (a,b), coronal (c,d) and sagittal planes (e,f)
through the isocenter.
treatments can be used resulting in a large improvement in dose homogeneity and conformity,
and in a reduction of the delivered dose to the critical structures. The reduction in minimal
distance between a jaw and the beam axis from 1.0 cm to 0.3 cm only requires a dedicated
handling of the input data for the treatment planning system. There is no need for additional
routine quality assurance procedures or workload. The technique can be applied in the clinic
for a large number of patients.
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Abstract
Purpose:
To investigate whether computer optimized fully non-coplanar beam set-ups may improve
treatment plans for the stereotactic treatment of liver tumors.
Methods:
An algorithm for automated beam orientation and weight selection (Cycle) was extended for
non-coplanar stereotactic treatments. For 8 liver patients previously treated in our clinic using
a prescription isodose of 65%, Cycle was used to generate non-coplanar and coplanar plans
with the highest achievable minimum PTV dose for the clinically delivered isocenter and
mean liver doses, while not violating the clinically applied hard planning constraints. The
clinical, and the optimized coplanar and non-coplanar plans were compared, with respect to
DPTV, 99%, the dose received by 99% of the PTV, the PTV generalized equivalent uniform
dose (gEUD) and the compliance with the clinical constraints.
Results:
For each patient the ratio between DPTV, 99% and Disoc, and the gEUD-5 and gEUD-20 values
of the optimized non-coplanar plan were higher than for the clinical plan with an average
increase of respectively 18.8% (range 7.8 – 24.0%), 6.4 Gy (range 3.4 – 11.8 Gy) and 10.3
Gy (range 6.7 – 12.5). DPTV, 99% / Disoc, gEUD-5 and gEUD-20 of the optimized non-copla-
nar plan was always higher than for the optimized coplanar plan with an average increase of
respectively 4.5% (range 0.2 – 9.7%), 2.7 Gy (range 0.6 – 9.7 Gy) and 3.4 Gy (range 0.6 –
9.9 Gy). All plans were within the imposed hard constraints. On average, the organs at risk
were better spared with the optimized non-coplanar plan than with the optimized coplanar
plan and the clinical plan.
Conclusions:
The use of automatically generated, fully non-coplanar beam set-ups results in plans that
are favorable compared to coplanar techniques. Due to the automation, we found that the
planning workload can be decreased from 1-2 days to 1-2 hours.
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3.1 Introduction
The number of patients with metastatic or primary liver tumors treated with external beam
radiotherapy is increasing. Often the patients treated with this modality can not be operated or
treated with another local modality such as radio frequency ablation (RFA), or percutaneous
ethanol injection therapy (PEI).
In some institutes, hypo-fractionated stereotactic radiotherapy is used[1–6], applying a
stereotactic body frame (SBF) with abdominal compression for reduction of respiratory tu-
mor motion. In 2002, using the Elekta SBF (Elekta AB, Stockholm, Sweden), this type of
treatment has been started in our clinic, for metastatic and hepatocellular carcinoma lesions.
Patients accepted for treatment can not be treated with surgery or other local treatments such
as RFA or PEI. The maximum allowed diameter of the lesion is 6 cm. With the patient
positioned in the SBF, arterial and venous contrast computed tomography (CT) scans are
made for tumor definition as well as a planning CT scan for contouring of the organs at risk
(OAR). Delineated tumors in the arterial and venous CT-scans are summed to construct the
definitive clinical target volume (CTV). To determine the required CTV-to-planning target
volume (PTV) margin, the residual respiratory tumor motion, is assessed with fluoroscopy
at a conventional simulator using implanted fiducials. The patients are treated mostly with
three fractions of 10-12.5 Gy (depending on disease type and tumor size), prescribed at the
65% isodose, that closely surrounds the PTV. This inhomogeneous dose concept is based on
the work of Lax et al. [7]. They showed that for a constant dose at the periphery of the PTV,
a 50% increase in the target center dose can be obtained, compared to a homogeneous dose
concept, without a substantial increase of dose to the normal tissue.
To irradiate liver tumors, most clinics use three-dimensional conformal radiotherapy
(3D-CRT) with a set of manually selected beam directions and forward treatment planning.
Generally, coplanar beam directions are used, while in some cases non-coplanar set-ups have
been applied[8,9]. Thomas et al. [10] investigated for a group of patients whether manually
chosen non-coplanar beam set-ups (i.e., with non-coplanar and coplanar directions) are more
favorable for intensity modulated radiation therapy treatment of liver tumors. They concluded
that for the group of patients with a tumor close to an OAR, the non-coplanar set-up improved
the treatment plan. For the other patients, the plans with a non-coplanar beam set-up were as
good as those with a 7 beam equidistant coplanar set-up or as those using the beam set-up of
the clinical plan.
In this paper, we have investigated the benefit of non-coplanar beam set-ups for hy-
pofractionated, stereotactic treatment of liver tumors, using automated beam direction selec-
tion from a large set of coplanar and non-coplanar input directions. For this purpose, our
in-house developed beam direction selection algorithm[11], Cycle, was extended for handling
of stereotactic (inhomogeneous) PTV dose distributions including an option for beam shape
optimization. For 8 liver patients previously treated in our clinic using a prescription iso-
dose of 65%, Cycle was used to generate non-coplanar and coplanar plans with the highest
achievable minimum PTV dose for the clinically delivered isocenter and mean liver dose.
The clinically applied hard planning constraints were also used for the automated plan gener-
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Structure Constraint Constraint
parameter
PTV DPTV, rel <DtolPTV, rel(n) NA
Normal liver Dmean <Dmean, clinical NA
Normal liver D50% <15 Gy D50% / 15
Normal liver D33% <21 Gy D33% / 21
Spinal cord Dmax <15 Gy Dmax / 15
Bowel, duodenum, D5 CC <21 Gy D5CC / 21
Stomach, esophagus,
Heart, aorta
Kidney’s D33% <15 Gy D33% / 15
R1 Dmax NA
R2 Dmax <20 Gy NA
Table 3.1: Applied constraints in the iterative optimization of the minimum PTV dose.
DtolPTV, rel(n) is the applied constraint level in iteration n on the relative PTV dose inhomogene-
ity. In the iterative procedure, DPTV, rel is minimized by repeated runs of Cycle with decreasing
values of DtolPTV, rel (see text). Da% indicates that a% of the volume receives a dose of at least
Da% and Da CC indicates that a CC receives a dose of at least Da CC. Structures R1 and R2 and
the maximum tolerated dose in R1 are defined in the text. The constraint parameters, Cj, for
OAR constraints, j, are required for calculation of the DIP (Eq. 3.2). NA = not applicable.
ation. The clinical, and the optimized coplanar and non-coplanar plans were compared, with
respect to DPTV, 99%, the dose received by 99% of the PTV, the PTV generalized equivalent
uniform dose (gEUD), and the distance from the applied constraint levels.
3.2 Methods
3.2.1 Description of liver plans
In clinical practice, the liver treatment plans were designed by a dosimetrist using forward
trial-and-error planning. Both coplanar and non-coplanar beams (open or wedged) could be
selected. For practical reasons not more than 10 different directions were allowed in a plan.
The dose (3×10 Gy or 3×12.5 Gy) was prescribed to the 65% isodose level. The clinical
treatment plans for the 8 patients in this study consisted of five to nine coplanar beams.
In addition, in Case 8, three non-coplanar beams were used. The workload of the manual
treatment plan generation was 1-2 days. The delineated OAR with their clinical constraints
are summarized in Table 3.1. Because the tumor location was heterogeneous among the
patient group, not all OARs were always relevant for all patients.
3.2.2 Short description of Cycle algorithm
The general principles of the Cycle algorithm for automated beam orientation and weight
selection have been described in detail by Woudstra et al. [11–14]. Here, a summary is given
with the focus on some extensions. The algorithm aims at generating a treatment plan with
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Pre-calculate dose distribution for each potential 
input beam direction
Optimize beam weight for each potential input 
direction based on score function
Select beam direction with maximum score
Calculate new dose distribution
Prescribed dose not yet attained?
And maximum number of directions not exceeded?
And constraints met (i.e. Score > 0)?
Plan generation succesful
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And constraints met (i.e. Score > 0)?
Start selection 
of next beam
No
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Start new plan generation
with adjusted importance 
factors.
Optimize beam shape for each potential input 
direction based on score function
Figure 3.1: Schematic diagram of the Cycle algorithm.
the prescribed tumor dose (isocenter), while not exceeding the imposed hard constraints. The
algorithm starts with an empty plan. Sequentially (Fig. 3.1), new beams are added to the
plan by selection from a large set of potential input directions based on a score function (see
section 3.A).
The selection of beams stops, if the selected beams result in a plan that can be scaled
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to the prescribed PTV dose without violation of any constraint level (the plan generation is
successful), or if no more beams can be added without violation of one of the constraints, or
if the number of allowed directions is reached. In the last two cases a new plan generation is
started with automatically adjusted penalty factors in the score function[11,12].
Strictly speaking, by itself Cycle is not an optimization algorithm; its aim is generation
of an acceptable plan (i.e., attaining the prescribed dose without exceeding the constraints).
The score function is used to build such an acceptable plan, and not to define and generate the
”best” plan. However, in an iterative loop, the algorithm may indeed be used to optimize a
plan parameter [14]. In this study, such a procedure was used to maximize the minimum PTV
dose (see section 3.2.5).
3.2.3 Beam shape optimization
Usually beam direction optimization for three-dimensional conformal radiotherapy is per-
formed with a fixed field/segment shape for each of the beam directions in the initial set [11–15].
Often the beams’ eye view (BEV) projection of the target and an additional margin for the
penumbra is used for the determination of the field shape[11,16].
In this paper, we study stereotactic treatments with highly inhomogeneous PTV dose
distributions that are very sensitive to the selected beam sizes. Because each selected beam
passes through the liver, each beam contributes to the mean liver dose. The contribution of
an individual beam is approximately proportional to the liver volume incorporated by that
beam, which is proportional to the area of the field of that beam. On average, the fields have
a diameter in the order of about 5 cm. An addition or subtraction of a margin of 0.5 cm from
the field shape, may therefore increase/reduce the field area by about 30%.
Therefore an extension was made to the Cycle algorithm, to enable optimization of the
field-shape for each input direction. First an initial field shape is made, based on the BEV
projection of the target (without penumbra margin). With this shape the beam weight is
optimized (see section 3.A). After that, the algorithm tries to further increase the score by
expanding or reducing the margin in small steps (2 mm), in four independent perpendicular
directions (+x, −x, +y, −y). Each step requires a recalculation of the off-axis dose dis-
tribution of the beam. A beam direction can be selected multiple times. In general, each
time it will be selected with a different shape and weight; therefore a plan can have multiple
segments per beam direction.
3.2.4 Input beam directions
For the coplanar plans, Cycle used 72 input beam directions evenly distributed in the axial
plane. For the non-coplanar plans, the input beam directions were distributed in separate sets
of 36 or 72 beam directions. The beam directions in each set have the same angle with the
axial plane, α, and they are evenly distributed with an equal separation in θ (see Fig. 3.2). For
α= 0 (i.e., the axial plane), the same 72 input beam directions were used as for the coplanar
plans. For sets with other α-values (i.e., for the non-coplanar input beams), 36 input beam
directions were used.
Increments in α of 10o were used. The upper and lower α were determined manually,
using the BEV (see Table 3.2). The set of non-coplanar beam directions with the αup or αlow
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Figure 3.2: Patient coordinate system and angles α, θ, for definition of the input non-coplanar
beam directions. O is the isocenter and, z is the cranial-caudal direction of the patient. OP is an
example of a beam direction. α is the angle of the xy-plane (axial plane) with OP.
is the set with the highest |α| for which none of the beams enters through the upper (cranial)
or lower (caudal) CT slice, i.e., αup and αlow were determined by the cranial-caudal extent of
the CT scan. If the separation between αup or αlow and the nearest set of input directions was
≥ 5o, an extra set of input beam directions was defined for αup or αlow.
3.2.5 Maximizing the minimum PTV dose
In the procedure to maximize the minimum PTV dose, the isocenter dose in the clinical
plan was used as the prescribed dose for the PTV, DprePTV. The minimum PTV dose was then
optimized in an iterative procedure, by minimizing the relative PTV dose inhomogeneity,
DPTV, rel=(Disoc-DPTV,min) / Disoc (see Table 3.1). In first instance, for the constraint on the
relative PTV dose inhomogeneity, DtolPTV, rel, the level of the clinical plan was used (35%). If
Cycle succeeded in generating a plan, the DtolPTV,rel level was decreased with a step of 1%.
This was repeated until plan generation was no longer successful, (i.e., DprePTV could not be
attained without a constraint violation). As mentioned above, the allowed maximum number
of beam directions in the clinical plans was 10. In order to generate clinically acceptable
plans, and for a straightforward comparison with the manually created clinical plans, the
allowed number of beam orientations in the Cycle plans was also limited to 10. Apart from
the DtolPTV,rel constraint, generation of plans was always subject to the constraints in Table 3.1.
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Case VPTV(CC) Vliver(CC) Prescription αlow αup No. of
dose (Gy) input beams
1 74.5 1271.0 3×12.5 -30 5 216
2 113.4 1228.0 3×12.5 -30 19 252
3 121.4 786.3 3×12.5 -30 10 216
4 105.9 1869.0 3×12.5 -30 5 216
5 211.8 1601.0 3×10.0 -20 10 180
6 46.9 1011.0 3×10.0 -30 20 252
7 111.2 985.9 5×5.0 -9 9 144
8 264.7 1632.0 3×12.5 -28 10 216
Table 3.2: Patient characteristics, the prescribed dose for the clinical plans (65 % isodose), the
αlow and αup defining the sets of input beam directions and, the number of input beam directions
for the non-coplanar plan.
To end up with a probability on liver complication for the optimized plans equal to or lower
than the clinical plan, the mean dose constraint on the normal liver volume (i.e., the entire
liver minus the CTV) was set to the clinically achieved mean normal liver dose value[17].
For cases 5-7, the clinical plan had a relatively low prescribed dose (Table 3.2). For these
patients, in a second step, an attempt was made to escalate the absolute isocenter PTV dose.
This was again done in an iterative way, by increasing the prescribed isocenter dose while
keeping the relative PTV dose inhomogeneity constraint, DtolPTV,rel, constant. For D
tol
PTV,rel, the
value used in the last iteration of the optimization procedure for the minimum PTV dose (see
previous) was used. The iterative procedure was stopped if further isocenter dose increase
was prevented by a constraint violation.
3.2.6 Non-organ specific regions in normal tissue
Apart from organ based constraints (e.g., for the kidney’s) for automated plan generation,
two other regions were defined in the normal tissue by expansions of the PTV (expansion 1
is the PTV plus a 2.0 cm margin, expansion 2 is the PTV plus a 5.0 cm margin). Region, R1,
was all tissue outside expansion 1 and inside expansion 2. Region, R2, was all tissue outside
expansion 2. For each region a maximum dose constraint was imposed (Table 3.1). The
constraint on R1 aims at conformality of the dose distribution to the target volume, while the
constraint on R2 avoids hot spots far away from the target volume. The value for the constraint
on R1 was chosen as 5-10 Gy lower than the minimum PTV dose level. The exact value of this
constraint was chosen in such a way, that it was not a limiting constraint for maximizing the
minimum PTV dose. If during the optimization process, a plan generation failed because of
violating this constraint, the constraint level was relaxed. For R2, a maximum dose constraint
of 20 Gy was used for each patient (Table 3.1).
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Case Clinical Coplanar Non-coplanar
1 61.0% 82.3% 85.0%
2 63.2% 76.6% 83.8%
3 70.4% 84.1% 88.4%
4 67.7% 80.0% 87.2%
5 69.1% 87.4% 87.6%
6 83.1% 87.9% 90.9%
7 61.6% 74.6% 84.3%
8 70.5% 88.6% 90.1%
Mean 68.3% 82.7% 87.2%
Table 3.3: DPTV, 99% / Disoc for the clinical and the optimized coplanar and non-coplanar plans.
3.2.7 Plan comparison
As described above, the main goal of the iterative use of Cycle was to maximize the minimum
dose in the PTV, while not exceeding the clinically delivered mean liver dose and without vio-
lation of the other clinical constraints. In this study, the ratio between DPTV,99%, the minimum
dose received by 99% of the PTV, and Disoc, the isocenter dose, was used for evaluation of
the plans. Also the gEUD of the PTV was evaluated using the following formula[18],
gEUDa =
(
1
N
N
∑
i=1
Dai
)1/a
(3.1)
With N the number of dose points, Di. The a parameter (a < 0) represents the aggres-
siveness of the tumor, with an increased aggressiveness for more negative a values. In this
study the gEUD was calculated with a-values of -5 and -20[10]. Potentially, an improved
DPTV,99% value for a constant mean normal liver dose could be accomplished at the cost of
a closer approach of other constraint levels. To evaluate this, the distance from ideal plan
(DIP), as defined by Woudstra et al. [12], was calculated for each plan.
DIP=
√√√√ M∑
j=1
C2j
M
(3.2)
In which Cj are the OAR constraint parameters as mentioned in Table 3.1. M is the
number of OAR constraints. For the optimized plans the maximum doses delivered to regions
R1 and R2 in the normal tissue were also evaluated. For plan evaluation, the maximum dose in
R1 was subtracted from DPTV,99%. This value represents the minimum dose gradient between
the PTV and region R1.
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3.3 Results
3.3.1 PTV: Optimized non-coplanar plan vs. clinical plan
The results for the PTV of the clinical, the coplanar and the non-coplanar plans are sum-
marized in Tables 3.3 and 3.4. For each case, DPTV,99%/Disoc and the gEUD-5 and gEUD-20
values were substantially higher for the optimized non-coplanar plan than for the clinical
plan. For DPTV, 99% / Disoc the average increase was 18.8% (range 7.8 – 24.0%). The average
increase for gEUD-5 and gEUD-20 was respectively 6.4 Gy (range 3.4 – 11.8 Gy) and 10.3
Gy (range 6.7 – 12.5 Gy) (Table 3.4). In Fig. 3.3, the dose volume histograms (DVH) of the
normal liver volume and the PTV are plotted for Case 2. The increase in PTV dose is clearly
visible. The high dose volume in the normal liver is slightly higher for the optimized plans,
because of the increase in minimum PTV dose. This increase is however compensated by a
smaller normal liver volume receiving a low dose, to end up with the same mean liver dose.
3.3.2 PTV: Coplanar vs. non-coplanar plan
In each case, the optimized non-coplanar plan was better than the optimized coplanar plan
(Tables 3.3 and 3.4). The increase in the ratio DPTV, 99% / Disoc was on average 4.5% (range
0.2 – 9.7%). The average increase in gEUD-5 and gEUD-20 was respectively 2.7 Gy (range
0.6 – 9.7 Gy) and 3.4 Gy (range 0.6 – 9.9 Gy) (Table 3.4). The total number of selected beam
directions was 10 for all of the optimized plans except for one case which had 9 directions for
the non-coplanar plan. The average ratio between the number of segments and the number of
beam directions in a plan was 2.0 (range 1.4 – 3.1) for the non-coplanar plans, and 2.7 (range
1.8 – 3.9) for the coplanar plans.
Resulting dose distributions of Case 2 are shown in Fig. 3.4. Because of the close
proximity of the heart, the aorta and the esophagus to the target and the eccentric position
of the target in the liver, this case was rather complicated. In the slice 2 cm cranial from the
a=-5 a=-20
Case A B C A B C
1 48.2 51.9 53.1 43.7 50.4 52.1
2 46.5 50.6 53.1 40.5 48.1 52.0
3 49.1 54.3 55.7 43.7 53.2 55.2
4 48.9 52.4 54.4 43.5 50.9 53.9
5 39.9 46.9 47.5 35.8 46.3 46.9
6 44.4 46.6 56.2 43.4 46.0 55.9
7 31.1 32.9 34.5 27.0 31.0 33.7
8 49.4 51.5 54.3 43.5 50.2 53.5
Mean 44.7 48.4 51.1 40.1 47.0 50.4
Table 3.4: gEUD-5 and gEUD-20 values for the clinical (A) and the optimized coplanar (B) and
non-coplanar plans (C).
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Figure 3.3: DVHs of the dose distributions in the PTV and the normal liver for the clinical plan
and the optimized non-coplanar and coplanar plans of Case 2.
isocenter slice, the increased dose homogeneity for the non-coplanar plan can be seen from
the 45 Gy isodose, which is at the edge of the PTV for the non-coplanar plan (Fig. 3.4(b))
and inside the PTV for the coplanar plan (Fig. 3.4(d)).
3.3.3 PTV: dose escalation
For Cases 5-7, it was tried to escalate the isocenter dose with a constant PTV inhomogeneity
as described above. Escalation succeeded for the Cases 5 and 6. The increase in Disoc with
respect to the clinical plan was 3.5 Gy and 2.9 Gy for respectively the non-coplanar plan and
the coplanar plan of Case 5 and 11.0 Gy and 1.5 Gy for respectively the non-coplanar plan
and the coplanar plan of Case 6. For the non-coplanar plan of Case 6, the iteration procedure
for minimization of the relative PTV dose inhomogeneity (first step, see section 3.2.5) was
stopped after the 90% PTV dose homogeneity level was reached, which was not the highest
achievable homogeneity level. This explains the large increase in Disoc. The liver volume in
Case 7 was relatively small (Table 3.2), and the PTV was situated in the center of the liver.
For Cases 5 and 6, the PTV was located at the edge of the liver. In the latter cases, beams
could be selected that involved a rather small volume of normal liver, whereas in Case 7 this
was not possible.
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Figure 3.4: Dose distributions for case 2 for the non-coplanar plan (a and b) and the coplanar
plan (c and d) for the isocenter slice (a and c) and a slice 2 cm cranial from the isocenter (b and
d). The dashed lines are the projections of the beam axis of the non-coplanar beam directions
in the axial slices, the solid lines are the beam axis of the coplanar beam directions. The labels
indicate the angle, α between the beam axis and the axial slices.
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DPTV, 99%-DR1, max DR2, max
Case A B C A B C
1 8.2 6.3 14.7 19.6 19.2 17.9
2 3.4 4.5 11.8 22.1 20.0 15.6
3 1.1 21.1 22.3 21.3 18.8 17.3
4 5.3 20.3 18.1 26.3 17.8 19.1
5 3.3 7.6 8.6 12.2 19.8 19.2
6 8.5 12.5 16.4 21.4 19.2 19.0
7 6.0 5.3 7.7 13.1 13.3 14.3
8 -0.1 1.5 8.0 24.7 19.9 18.7
Table 3.5: Comparison between the clinical (A), the coplanar(B), and the non-coplanar (C)
plans with respect to the maximum dose delivered to the normal tissue regions R1 and R2.
3.3.4 Normal tissues
As aimed for, all optimized plans delivered the clinically prescribed isocenter dose with the
same mean liver dose as for the clinical plan, without violation of the normal tissue con-
straints. The mean liver dose constraint was the limiting constraint for further increase of the
minimum PTV dose in each case. In Table 3.5, the clinical plan and the optimized coplanar
and non-coplanar plans are compared with respect to the maximum doses in the regions R1
and R2. In 6 of the 8 cases, the optimized coplanar plans have a higher difference between
DPTV,99% and the maximum dose in R1, than the clinical plans. In 7 of the 8 cases, the op-
timized non-coplanar plans have a higher DPTV, 99%-DR1, max, than the optimized coplanar
plans. In 6 of the 8 cases the maximum dose in R2 is lower for the optimized coplanar plan
than for the clinical plan. In 6 of the 8 cases the maximum dose in R2 is lower for the
non-coplanar plan than for the coplanar plan.
The DIP was calculated for each case as explained in section 3.2.7. The average DIP
of the optimized non-coplanar plans was both lower than the DIP for the clinical plans, and
lower than the DIP for the optimized coplanar plans (Table 3.6). Tables 3.3-3.6 illustrate that
non-coplanar beam set-ups allow the highest minimum PTV doses, and gEUD-5 and gEUD-20
values, while avoiding most approaching OAR constraint levels.
3.4 Discussion
Automatically optimized beam selection for stereotactic treatment of liver tumors results in
increased DPTV, 99% values compared to the clinical plan, for the same isocenter and mean
normal liver doses, without violation of the clinical constraints, and even avoiding best ap-
proaching these constraints. For non-coplanar beam set-ups the improvement in DPTV, 99%
is higher than for coplanar beam set-ups. Automatically selected non-coplanar beam set-ups
also have a higher dose gradient between the PTV and the normal tissue region R1 than the
automatically selected coplanar beam set-ups, and on average a lower DIP than the coplanar
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Case Non-coplanar Coplanar Clinical
1 0.025 0.115 0.094
2 0.224 0.264 0.254
3 0.257 0.292 0.293
4 0.223 0.255 0.205
5 0.169 0.160 0.161
6 0.159 0.213 0.246
7 0.175 0.137 0.155
8 0.240 0.243 0.231
Mean 0.184 0.210 0.205
Table 3.6: Distance from ideal plan for the optimized coplanar and non-coplanar plans and the
clinical plan.
plans. A plan produced by Cycle has an optimal number of beams, in the sense that Cy-
cle stops adding beams when the prescribed dose is attained. In this study, the number of
selected beam directions was dependent on how strict the relative PTV dose inhomogeneity
constraint, DtolPTV, rel, was set. In the first steps of the iterative optimization procedure, when
DtolPTV,rel was not very strict (see section 3.2.5), the number of selected beam directions was
usually lower than 10. With the DtolPTV,rel constraint becoming more strict, the number of se-
lected directions increased, until the maximum number of allowed beams per plan (i.e., 10)
was reached. Unlike the number of beam directions, the number of segments was not limited
in the plan optimization. It was demonstrated that in a coplanar plan the average number of
beam segments per beam orientation was substantially higher than for the non-coplanar plan
(2.7 vs. 2.0).
Except for one case, the number of beam directions for the plans generated by Cycle was
10. With regard to the required treatment time, this might be a high number, especially for
non-coplanar cases because of the need for couch rotation. However, the treatment is given
in only three fractions. So the relative effect of the high number of beams on the treatment
time is much less than for a treatment with a conventional fractionation scheme. For most
cases all selected directions are non-coplanar directions. Cases 5 and 8 had respectively 6
and 7 non-coplanar directions in the beam set-up of the non-coplanar plan. These two cases
had the lowest improvement in DPTV, 99%, see Table 3.3.
Thomas et al. [10] also investigated the use of non-coplanar beam set-ups for treatment
of liver tumors, comparing three IMRT plans, each with a different beam set-up. One set-up
contained non-coplanar directions, one set-up used the directions applied in the clinical plan
and one set-up used 7 equidistant coplanar directions. They saw that the non-coplanar beam
set-up was only favorable in cases where the PTV incorporated another OAR besides the
liver. In our study we see a clear advantage of applying non-coplanar directions in the beam
set-up for each case. A reason for these different observations might be that in our study the
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non-coplanar beam directions are computer optimized for each individual patient, which is
not the case in the study by Thomas et al. Moreover in our study relatively small tumors are
considered with small CTV-PTV margins, resulting from the abdominal compression, treated
with stereotactic (inhomogeneous) PTV dose distributions.
The maximum calculation time for a plan with Cycle (allowing 10 restarts with adjusted
penalty factors, see above) on a workstation with an Intel Xeon 3.2 GHz processor was 2
hours for a non-coplanar plan. For coplanar planning this calculation time was reduced by a
factor of three.
In this study, we have assumed that the probability of liver complications is correlated
with the mean normal liver dose, as found by Dawson et al. [17]. Recently, Cheng et al. [19]
showed for the treatment of primary tumors, that for HBV carriers and/or Child Pugh grade
B, this probability might be more correlated with the high dose delivered to the normal liver.
Separate analysis would be required to assess the advantage of non-coplanar beam set-ups
for these cases.
For all patients, the tumor was located in the upper part of the set of CT-slices. There-
fore, for 6/8 patients, αup was not larger than 10o (Table 3.2), so only one set of non-coplanar
directions entering the patient from the cranial direction could be defined. Despite the small
angles between these non-coplanar directions and the axial plane, the non-coplanar plans are
better than the coplanar plans for these six patients. A larger improvement may be expected
if a larger part of the patient in the cranial direction is scanned.
Here, we have investigated the use of computer optimized non-coplanar beam set-ups
to improve the PTV dose distribution for liver tumors treated with stereotactic radiotherapy.
It was decided to aim at an increase in the minimum PTV dose in order to better approach
the homogeneous PTV dose distribution in conventional radiotherapy. Cycle would also have
allowed escalation of the isocenter dose while keeping the dose inhomogeneity constant, or
escalation of the PTV gEUD. The choice to focus on elevation of the minimum PTV dose
is in line with recent findings of Wulf et al. [20] who found that in stereotactic treatment of
lung tumors the dose at the PTV margin was the only significant variable for local control.
Currently, integration of Cycle in the commercial treatment planning system XIO (CMS, Inc.,
St. Louis, MO) is being investigated.
3.5 Conclusions
The use of automatically optimized non-coplanar beam set-ups for stereotactic treatment of
liver tumors results in treatment plans with improved PTV coverage and reduced dose deliv-
ery to healthy tissues. Compared to manual forward planning, the planning workload can be
reduced from 1-2 days to 2 h at maximum.
3.A Appendix: Beam selection and score function
For the selection of a beam, each input beam direction is temporarily added to the plan and
its weight and shape are optimized based on a score function. The beam direction with
the highest score is selected. The score function in Cycle is based on a trade-off between
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increasing the PTV dose and approaching the constraint levels for the PTV and the normal
tissues. Touching or exceeding a hard constraint results in a zero score. The hard constraints
used in this study are given in Table 3.1.
The score function, Sk, for the selection of beam k is given by,
Sk(ψ,φ,w) = S1PTV ,k ·S2PTV ,k ·∏
j
S j,k ·Sliver,mean,k (3.3)
with,
S1PTV ,k =
ΔDPTV (ψ,φ,w,k)
ΔDprePTV (k)
(3.4)
S2PTV ,k =
[
1− DPTV ,rel(ψ,φ,w,k)
DtolPTV ,rel
· f b
]p
(3.5)
S j,k =
[
1− ΔPj(ψ,φ,w,k)
ΔPtolj (k)
]p j
(3.6)
Sliver,mean,k=
[
1− ΔPj(ψ,φ,w,k)
ΔPtolj (k)
·
(
ΔDprePTV (k)
ΔDPTV (ψ,φ,w,k)
)a]p
(3.7)
and:
• Δ DPTV (ψ,φ,w,k) the increase in the delivered PTV dose (isocenter), because of the
addition of a beam k with gantry angleψ, couch angle φ, and weight w to the previously
selected k−1 beams.
• Δ DprePTV (k), the prescribed PTV dose minus the PTV dose (isocenter) delivered by the
first k−1 beams.
• DPTV, rel (ψ,φ,w,k), the relative PTV dose inhomogeneity ( = (Disoc, k -DPTV, min, k) /
Disoc, k ) after the addition of a beam k, with ψ, φ, and w.
• DtolPTV, rel, the tolerated relative PTV dose inhomogeneity (DprePTV - DtolPTV, min )/DprePTV.
• f=( Disoc, k / DprePTV), the ratio between the isocenter dose after the addition of beam k
and the prescribed dose.
• Δ Pj (ψ,φ,w,k), the increase in the dose distribution parameter Pj (e.g., the maximum
dose delivered in an OAR), because of the addition of a beam k, with ψ, φ, and w.
• Δ Ptolj (k), the tolerance value for parameter Pj (e.g. the maximum dose allowed in an
OAR) minus the parameter value resulting from the previously selected k−1 beams.
• pj, penalty factor that determines the penalty for approaching constraint j.
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S1PTV ,k in Eq. 3.4 ensures that the score increases with increasing isocenter dose. The
extent of the increase depends on the penalty terms S2PTV ,k, S j,k and Sliver,mean,k, which de-
crease if w goes up because of a closer approach to the constraints. S2PTV ,k (Eq. 3.5) and
Sliver,mean,k (Eq. 3.7) prevent violation of the relative PTV dose inhomogeneity constraint
and the mean liver dose constraint, respectively. The terms S j,k (Eq. 3.6) impose a penalty
for approaching the other hard constraints.
The dose distribution after the first selected beam will generally have a rather high rel-
ative PTV dose inhomogeneity, because the attenuation of this beam is not yet compensated
by beams from other directions. The term f b in S2PTV ,k (b = 0.5 in this study) allows for
exceeding of the tolerated relative PTV dose inhomogeneity, DtolPTV ,rel , for selection of the
first beams. If the isocenter dose approaches the prescribed dose, f b goes to 1 and the rela-
tive dose inhomogeneity, DPTV ,rel(ψ,φ,w,k), is forced to become smaller than the tolerated
inhomogeneity. If the value of the dose distribution parameter Pj is much smaller than the
tolerated value (which is the case in the first selected beams) the penalty term S j,k (Eq. 3.6)
is less sensitive to an increase in Pj than when Pj is close to the tolerated dose. This may
result in selection of beam directions that pass through OARs. For most OARs this is not a
problem, because in a further stage of the plan generation, beam directions will be selected
that avoid this OAR. As the PTV is located inside the liver, this OAR can not be avoided by
any beam direction. In addition, the mean liver dose constraint is the most limiting constraint.
Therefore it is important that also for the selection of the first beams the score is sensitive to
the mean liver dose parameter. This has been solved by a generalization of the term S j,k (Eq.
3.6), yielding Sliver,mean,k (Eq. 3.7), with Pj = Dliver,mean. If a equals 0, Sliver,mean,k is the
same as S j,k. In this study, a value of 0.5 has been used.
Bibliography
[1] Hadinger U, Thiele W, Wulf J. Extracranial stereotactic radiotherapy: evaluation of PTV coverage
and dose conformity Z Med Phys. 2002;12:221–229.
[2] Wulf J, Hadinger U, Oppitz U, et al. Stereotactic radiotherapy for primary lung cancer and pul-
monary metastases: a noninvasive treatment approach in medically inoperable patients Int J Radiat
Oncol Biol Phys. 2004;60:186–196.
[3] Wulf J, Hadinger U, Oppitz U, et al. Impact of target reproducibility on tumor dose in stereotactic
radiotherapy of targets in the lung and liver Radiother Oncol. 2003;66:141–150.
[4] Wulf J, Hadinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver
Strahlenther Onkol. 2001;177:645–655.
[5] Schefter TE, Kavanagh BD, Timmerman RD, et al. A phase I trial of stereotactic body radiation
therapy (SBRT) for liver metastases Int J Radiat Oncol Biol Phys. 2005;62:1371–1378.
[6] Timmerman RD, Kavanagh BD. Stereotactic body radiation therapy Curr Probl Cancer.
2005;29:120–157.
[7] Lax I. Target dose versus extratarget dose in stereotactic radiosurgery Acta Oncol. 1993;32:453–
457.
Chapter 3 51
[8] Park W, Lim DH, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular
carcinoma Int J Radiat Oncol Biol Phys. 2005;61:1143–1150.
[9] Ten Haken RK, Balter JM,Marsh LH, et al. Potential benefits of eliminating planning target volume
expansions for patient breathing in the treatment of liver tumors Int J Radiat Oncol Biol Phys.
1997;38:613–617.
[10] Thomas E, Chapet O, Kessler ML, et al. Benefit of using biologic parameters (EUD and
NTCP) in IMRT optimization for treatment of intrahepatic tumors Int J Radiat Oncol Biol Phys.
2005;62:571–578.
[11] Woudstra E, Storchi PR. Constrained treatment planning using sequential beam selection Phys Med
Biol. 2000;45:2133–2149.
[12] Woudstra E, Heijmen BJM. Automated beam angle and weight selection in radiotherapy treatment
planning applied to pancreas tumors Int J Radiat Oncol Biol Phys. 2003;56:878–888.
[13] Woudstra E, Heijmen BJM, Storchi PR. A comparison of an algorithm for automated sequential
beam orientations selection with exhaustive search and simulated annealingMed Phys. 2005.
[14] Woudstra E, Heijmen BJ, Storchi PR. Automated selection of beam orientations and segmented
intensity-modulated radiotherapy (IMRT) for treatment of oesophagus tumors Radiother Oncol.
2005;77:254–261.
[15] Beaulieu F, Beaulieu L, Tremblay D, et al. Simultaneous optimization of beam orientations,
wedge filters and field weights for inverse planning with anatomy-based MLC fields Med Phys.
2004;31:1546–1557.
[16] Beaulieu F, Beaulieu L, Tremblay D, et al. Automatic generation of anatomy-based MLC fields in
aperture-based IMRTMed Phys. 2004;31:1539–1545.
[17] Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the
Lyman NTCP model Int J Radiat Oncol Biol Phys. 2002;53:810–821.
[18] Niemierko A. A generalized concept of equivalent uniform dose (EUD)Med Phys. 1999;26:1100.
[19] Cheng JC, Wu JK, Lee PC, et al. Biologic susceptibility of hepatocellular carcinoma pa-
tients treated with radiotherapy to radiation-induced liver disease Int J Radiat Oncol Biol Phys.
2004;60:1502–1509.
[20] Wulf J, Baier K, Muller G, et al. Dose-response in stereotactic irradiation of lung tumors Radiother
Oncol. 2005;77:83–87.

Chapter 4
PTV dose prescription strategies for SBRT of metastatic liver
tumors
JA de Pooter, W Wunderink, A Me´ndez Romero, PRM Storchi, BJM Heijmen, Radiother Oncol.
2007;85(2):260-6
54 Chapter 4
Abstract
Purpose:
Recently we have demonstrated that our in-house developed algorithm for automated plan
generation for fully non-coplanar SBRT of liver patients (designated Cycle) yields plans that
are superior to conventionally generated plans of experienced dosimetrists. Here we use
Cycle in the comparison of plans with prescription isodoses of 65% or 80% of the isocenter
dose.
Methods:
Plans were generated using CT-data of 15 previously treated patients. For each patient, both
for the 65%- and the 80% strategy, Cycle was used to generate a plan with the maximum
isocenter dose, Disoc, while strictly obeying a set of hard constraints for the organs at risk
(OAR). Plans for the two strategies were compared using Disoc, DPTV, 99% (the minimum dose
delivered to 99% of the PTV), and the generalized equivalent uniform dose, gEUDPTV(a), for
several values of the parameter a. Moreover, for the OARs, the distance to the constraint
values was analysed.
Results:
The 65% strategy resulted in treatment plans with a higher Disoc (average 17.6%, range 7.6%
– 31.1%) than the 80% strategy, at the cost of a somewhat lower DPTV,99% (average -2.0%,
range -9.6% – 9.3%). On average, voxels with a dose in the 65% strategy, lower than the
minimum PTV dose in the 80% strategy, were within 0.2 cm from the PTV surface. For a ≥
-10, the 65% strategy yielded on average a significantly (P<0.01) higher gEUDPTV(a) than
the 80% strategy, whereas for highly negative a-values the 80% approach was slightly better,
although not significantly. Large variations between patients were observed. Generally, for
the OAR the approach to the constraint levels was similar for the two strategies.
Conclusion:
On average, PTV dose delivery is superior with the 65% strategy. However, apart from the
isocenter dose, for each applied PTV dose parameter at least one patient would have been
better off with the 80% dose prescription strategy.
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4.1 Introduction
In treatment plan design for stereotactic body radiation therapy (SBRT) of liver metastases,
different dose prescription strategies are applied. Some institutes prescribe the dose to the
65%[1–4] isodose, other institutes [5,6] prescribe to the 80% isodose, resulting in treatment
plans with an inhomogeneous and a more homogeneous PTV dose distribution respectively.
In both strategies, the prescription isodose closely surrounds the PTV. The 65% dose pre-
scription strategy is based on the work of Lax[7], who investigated the trade-off between
target dose and normal tissue dose for stereotactic radiosurgery. He found that an inhomo-
geneous PTV dose distribution (Dmin / Dmax = 60%) yields an increased mean PTV dose
compared to a more homogeneous PTV dose distribution (Dmin / Dmax = 85%), for the same
dose at the periphery of the PTV, and for almost the same dose to the normal tissue. He
used a 4π-beam distribution with 201 equally weighted cone shaped beams to simulate an
intra-cranial treatment performed with a gamma-knife.
SBRT for liver metastases differs from the radiosurgery treatment simulated by Lax
on the following aspects. SBRT is performed with a linear accelerator using a relatively
small number of MLC shaped coplanar and non-coplanar beams (in our case 10 beams at
maximum). The angle of the non-coplanar directions with the axial plane is limited due to
forbidden couch-gantry angle combinations. The purpose of this paper is to compare the 65%
and 80% strategy for SBRT of liver metastases.
4.2 Methods
4.2.1 Automatic plan generation with Cycle
In this study, plans are automatically generated using an in-house developed algorithm, des-
ignated Cycle. The algorithm has been described in detail [8–10], here a short summary is
given. Cycle aims at generating a treatment plan with the prescribed PTV isocenter dose,
while strictly obeying the imposed constraint levels on the PTV dose inhomogeneity, OARs
and other normal tissues. Cycle starts plan generation with an empty plan. Sequentially
new beam directions are selected and added to the plan from a large set of input directions
containing coplanar and non-coplanar beams. Dose distributions for input directions are pre-
calculated, with a pencil beam algorithm.
To select a new beam, k, each beam in the set of input directions is temporarily added to
the plan (consisting of the previously selected k-1 beams). For each temporarily added input
beam direction, the weight and beam shape are optimised, based on a score function. The
score function represents a trade-off between increasing the PTV dose and approaching the
imposed constraint levels. The score function takes into account the dose distribution of the
previously selected k-1 beams. The optimized score, smax, for all beam directions in the input
set are compared and the beam direction with the highest score is selected and added to the
plan. The score function can be made more sensitive for a certain constraint by increasing
the corresponding importance factor. Further selection of beams stops if one of the following
is true:
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• Maximum number of allowed beam directions per plan is reached
• A constraint is violated
• The prescribed dose has been attained, i.e., plan generation was successful
In the first two situations a new plan generation is started with automatically adjusted
importance factors for the score function to better avoid approaching critical constraints. In
this study, for each patient and each strategy, Cycle was used repeatedly for increased doses
to generate the plan with the highest prescribed isocenter dose, while not violating any of the
constraints.
4.2.2 Input beam directions
In a previous paper we showed the advantage of automatically generated fully non-coplanar
beam set-ups[8]. Therefore in this study, the set of input beam directions consisted of 72
coplanar beams and a number of sets of 36 non-coplanar beams. Each set of non-coplanar
beams had a constant angle, α, with the axial plane. The separation in α between two sets
was 10o. The maximum α for which none of the input beam directions enters the CT patient
volume through the upper or lower CT slice was determined for each patient individually.
The maximum α determines the number of sets of non-coplanar input beam directions. In
this study the number of beams in the input set ranged from 216 to 252 (including the 72
coplanar beams).
4.2.3 Planning constraints
The clinical planning constraints used in this study are summarized in Table 4.1. For the
OARs, the constraints of the clinical protocol are used. Due to a history of surgical resection,
some patients have a rather small liver volume. For these patients applying only the dose
volume histogram (DVH) liver constraints, defined as a fixed percentage (33% and 50%) of
the total liver volume may result in a small absolute liver volume that receives a low dose. To
avoid this, the DVH constraint proposed by Schefter et al. [6] was applied, which states that at
least 700 CC of the normal liver volume should receive a dose lower than 15 Gy.
Maximum dose constraints were applied to two non-organ-based regions in the normal
tissue. Region R2 is defined as all tissue outside a PTV expansion of 5.0 cm. Region R1 is
defined as all tissue outside a PTV expansion of 2.0 cm, excluding region R2.
4.2.4 Plan optimisation
For CT-data of 15 patients previously treated at our institute [2] Cycle was used to generate
plans for the two strategies. For both strategies, the isocenter dose was maximised, while
keeping the ratio between the minimum PTV dose and the prescribed isocenter dose, constant
at either 65% or 80%. The constraints mentioned in Table 4.1 were hard constraints, so no
constraint violations were allowed. The maximum number of beams allowed per plan was
set to 10. The spherically shaped PTV and CTV have average volumes of respectively 146
CC (49 – 405 CC) and 56 CC (12 – 200 CC).
For isocenter dose maximisation Cycle was used in an iterative procedure. In each iter-
ation, Cycle tried to generate a plan with the prescribed isocenter dose, while strictly obeying
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Structure Constraint Cj
PTV DPTV, min = 0.65 or 0.80 × Disoc NA
Liver D33% < 21 Gy D33% / 21
Liver D50% or D700 CC < 15 Gy D50% / 15
Spinal Cord Dmax < 15 Gy Dmax / 15
Bowel, duodenum, D5 CC < 21 Gy D5 CC / 21
stomach, esophagus
Heart D5CC < 21 Gy D5 CC / 21
Kidney’s D33% < 15 Gy D33% / 15
R1 Dmax < DPTV, min - 5 Gy NA
R2 Dmax < 20 Gy Dmax / 20
Table 4.1: Applied constraints for the plan optimisation and their corresponding constraint
parameters, Cj, for the calculation of the DIP (Eq. 4.2).
the imposed constraints. If the plan generation was successful, the prescribed isocenter dose
was slightly increased. This was repeated until further increase of the prescribed isocenter
dose did no longer result in a plan without constraint violation even after repeated adjust-
ments of the importance factors in the score function (see above). For plan generation, the
relative PTV dose inhomogeneity constraint DtolPTV, rel = (D
pre
PTV - D
tol
PTV, min) / D
pre
PTV was set to
0.35 and 0.2 for the 65% and the 80% strategy respectively[8], where DprePTV is the prescribed
isocenter dose and DtolPTV, min the tolerated minimum PTV dose.
4.2.5 Comparison of strategies
For the PTV, optimal plans for the two strategies were compared with respect to the gener-
alised equivalent uniform dose, gEUD, mean dose, isocenter dose and DPTV, 99% (the mini-
mum dose delivered to 99% of the PTV). The gEUD(a) is given by the following formula.
gEUD(a) =
(
1
N
N
∑
i=1
Dai
)1/a
(4.1)
Here a is a tissue specific parameter which is negative for tumors[11]. The summation
is over N voxels with index i. Since the exact value of a for liver metastases is unknown,
the comparison was done for the following levels of a: -100, -50, -20, -10, -5, -1. Statistical
significance was tested with a paired two-tailed t-test.
As expected it turned out, that the inhomogeneous 65% planning strategy led to the
highest isocenter dose. However, some patients had voxels close to the PTV surface with a
dose lower than the minimum dose in the 80% strategy. To evaluate the importance of this
PTV volume receiving a low dose with the 65% strategy, gEUDPTV-0.25(a) and DPTV-0.25, 99%
values were calculated for the PTV minus a margin of 0.25 cm. Moreover, the fraction of the
PTV voxels for which the 65% strategy receives a lower dose than the minimum PTV dose
of the 80% strategy, F(D65%j < D
80%
PTV,min), and the maximum distance, dmax, of these voxels
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to the PTV surface was calculated. To calculate dmax, a triangulation of the PTV surface was
made based on the available PTV contour points. Then, for each PTV voxel that received for
the 65% strategy a dose lower than the minimum PTV dose of the 80% strategy, the distances
between the voxel and all the PTV surface triangles were calculated. The minimum of these
distances was the distance of the voxel from the PTV surface.
Figure 4.1: Relative differences between the 65% and 80% strategies in the parameters (indi-
cated by X on the left axis) DPTV, 99%, DPTV, mean, Disoc, and gEUDPTV(a) for a–values ranging
from -100 to -1. The dots represent comparisons for individual patients. The line connects
patient mean values.
To evaluate the dose delivered to the OARs, the distance from ideal plan[8,10], DIP,
and the conformality index, CI, were calculated for each plan. The DIP measures how far
an optimised plan stays away from the applied constraint levels. The DIP is given by the
following formula,
DIP=
√√√√ M∑
j=1
C2j
M
(4.2)
M is the number of OAR constraints. Cj, the constraint parameter for the j-th constraint,
is the ratio between its actual level and the applied constraint level, see Table 4.1. CI is
defined in this study as the ratio between the volume of the DPTV, 99% isodose and the total
PTV volume. Per plan and per strategy, the limiting structures were evaluated. The limiting
structure is that structure, where constraints prevent further increase of the isocenter dose
(section 4.2.4).
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4.3 Results
4.3.1 PTV evaluation
Results for the isocenter dose, PTV mean dose, DPTV, 99% and gEUDPTV(a) comparisons are
shown in Fig. 4.1. For a ≥ -20 the gEUD(a) for the 65% strategy plans is on average higher
than for the 80% strategy, with a considerable variation between individual patients. For a =
-20 and a = -10 the increase for the 65% strategy is on average 1.4% (range -6.3% – 12.3%)
and 4.8% (range -4.1% – 15.8%) respectively. The increase is significant for a ≥ -10 (P <
0.01), for a ≤ -20 and for the DPTV, 99% both strategies are not statistically different. The
isocenter dose and the mean PTV dose are on average higher for the 65% strategy, 17.6%
(range 2.9% – 31.1%), and 9.8% (range -1.4% – 20.2%), respectively.
Results for the PTV minus a margin of 0.25 cm are shown in Fig. 4.2. For each strategy
and each a parameter the gEUDPTV-0.25(a) of a plan is higher than the gEUDPTV(a). This
increase in gEUDPTV-0.25(a) is higher for the 65% strategy than for the 80% strategy, resulting
in larger mean relative differences between the strategies. The average of gEUDPTV-0.25(a)
for the 65% strategy is higher than for the 80% strategy for each value of the a-parameter.
The differences are significant for a ≥ -20 (P < 0.01), for lower a-values both strategies
are not statistically different. For a = -20 and a = -10 the gEUD for the 65% strategy is on
average 6.4% (range -2.6% – 18.2%) and 8.8% (range -1.4% – 20.4%) higher, respectively.
DPTV-0.25, 99% is on average 2.8% higher for the 65% strategy, however the increase is not
Figure 4.2: Relative differences between the 65% and 80% strategies in the parameters (in-
dicated by X on the left axis) DPTV-0.25, 99%, D PTV-0.25, mean, Disoc and gEUDPTV-0.25(a) for
a–values ranging from -100 to -1. The dots represents comparisons for individual patients. The
line connects patient mean values.
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statistically significant (P = 0.132).
The results for F(D65%j < D
80%
PTV,min) are shown in Table 4.2. On average 3% (range 0%
– 9%) of the PTV voxels receive for the 65% strategy plan a dose lower than the minimum
PTV dose of the 80% strategy plan. The maximum distance, dmax, of these voxels to the
PTV surface has for the whole patient group an average value of 0.16 cm with a maximum
of 0.48 cm (Table 4.2, last column). The voxels of the PTV for which the 65% strategy is
lower than the minimum PTV dose of the 80% strategy are categorised according to their
difference between the dose received for the 65% strategy and the minimum PTV dose of
the 80% strategy. For the voxels in each category the maximum distance, dmax, to the PTV
surface was calculated (see column 3-6 of Table 4.2). It can be seen that dmax, increases with
a decreasing dose difference. For voxels receiving in the 65% strategy a dose more than 5%
lower than the minimum PTV dose of the 80% strategy the highest dmax in the patient group
is 0.31 cm.
Fig. 4.3 shows for case 4 dose distributions in the isocenter plane for the 65% strategy
(Fig. 4.3(a)) and the 80% strategy (Fig. 4.3(b)), and a crossline dose profile (Fig. 4.3(c)).
The dose in the central part of the PTV is considerably higher for the 65% strategy. From the
Case F dmax (cm)
0 - 2% 2 - 5% 5 - 10% 10 - 15% Overall
1 0.02 0.10 0.11 0.11
2 0.02 0.16 0.13 0.16
3 0.05 0.48 0.45 0.31 0.09 0.48
4 0.06 0.31 0.22 0.22 0.31
5 0.00 0.00
6 0.03 0.06 0.18 0.18
7 0.00 0.00
8 0.01 0.11 0.11
9 0.02 0.21 0.21
10 0.02 0.11 0.03 0.11
11 0.04 0.18 0.26 0.21 0.26
12 0.03 0.19 0.18 0.08 0.19
13 0.09 0.23 0.25 0.18 0.09 0.25
14 0.00 0.00
15 0.00 0.00
Average 0.03 0.19 0.20 0.20 0.09 0.16
Table 4.2: Data on PTV voxels for which the dose in the 65% strategy is lower than the min-
imum dose of the 80% strategy. F is the fraction of these PTV voxels. dmax is the maximum
distance of these voxels to the PTV surface. In columns 3-6 the voxels are categorized accord-
ing to their dose difference with the minimum PTV dose for the 80% strategy. The last column
show overall dmax values.
Chapter 4 61
crossline profile it can be seen that there is a small volume at the edge of the PTV that receives
a dose lower than the minimum dose level of the 80% strategy. This small underdosage at
the PTV edge is not observed for each crossline profile. The selected isocenter slice dose
distribution is a worst case for the whole patient group.
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Figure 4.3: PTV contour (thick grey polyline) and dose distributions for case 4 for the 65% (a)
and the 80% strategy (b) in the isocenter slice. Only isodoses (in Gy) between the minimum and
maximum PTV dose are plotted. (c) crossline profiles of the distributions in a. and b. plotted
with the minimum dose level of the 80% strategy (horizontal line) and the edges of the PTV
(thick vertical lines).
62 Chapter 4
Case DIP Limiting constraints
65% 80% 65% 80%
1 0.240 0.237 Liver, NT Liver, NT
2 0.268 0.258 Myelum, Heart Myelum, Heart
3 0.299 0.295 Kidney, NT Kidney, NT
4 0.274 0.260 Esophagus, NT Myelum, Bowel, NT
5 0.233 0.222 Myelum, NT NT
6 0.264 0.278 Liver Liver
7 0.207 0.200 Liver Liver
8 0.281 0.268 Heart, NT Heart, NT
9 0.216 0.222 NT NT
10 0.240 0.256 NT NT
11 0.286 0.278 NT NT
12 0.239 0.253 NT Bowel, NT
13 0.254 0.261 Bowel, NT Bowel, NT
14 0.233 0.244 Esophagus Esophagus, NT
15 0.280 0.280 Myelum, Heart Myelum
0.254 0.254
Table 4.3: DIP (Eq. 4.2) values calculated for the 65% and the 80% strategy. Structures with
limiting constraints for both strategies. NT indicate the normal tissue constraints on R1 and R2.
4.3.2 Normal tissue evaluation
The results for the DIP calculations are shown in Table 4.3. The differences in DIP value
between the two strategies are rather small. The CI of the generated plans had a mean value
of 1.26 (range 1.14 – 1.38) and 1.18 (range 1.09 – 1.31) for the 65% and the 80% strategy,
respectively. In Table 4.3, also the limiting structures are summarized per case and per plan-
ning strategy. Further increase of PTVwas prevented by violation of one or more OAR and/or
normal tissue constraints in combination with the minimum PTV dose constraint. For 10/15
patients the complete set of limiting structures is the same in both strategies (Table 4.3). For
the other five cases at least one limiting structure is the same in both strategies.
4.4 Discussion
The 65% strategy results in plans that have a considerably higher peak dose in the central part
of the PTV (isocenter dose) than for the 80% strategy, at the cost of a somewhat lower dose
in voxels close to the boundaries of the PTV. The OAR dose is on average the same for both
strategies and within the applied planning constraint levels. The conformality as measured
with the CI is somewhat higher for the 65% strategy, and within the limit of 1.4 as proposed
by Timmerman et al [12].
The considerable increase in mean PTV dose for the 65% planning strategy is in agree-
ment with the results of Lax[7]. He found an increase of 29% in the mean PTV dose if a dose
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concept with a high PTV dose inhomogeneity was applied instead of a concept with a low
PTV dose inhomogeneity, while in this study the increase was 9.8% on average. The higher
value found by Lax can be partially explained by differences in the planning approach. In
our approach the OAR constraints were constant for both strategies, while in the approach
of Lax the dose at the periphery of the PTV was constant. Furthermore, the strategies in the
study of Lax have different PTV dose inhomogeneities, 60% and 85%, than the ones used in
this study, 65% and 80%. Also, the study of Lax was designed to simulate an intra-cranial
radiosurgery treatment using a large number of cone shaped beams, while in this study the
maximum number of beams per plan was set to 10. In theory, the conclusions in this pa-
per could be biased by selection of tuning parameters of the Cycle algorithm for the 65% and
80% strategies. However, there are only a few tuning parameters, that have been established a
long time ago[9]. For both strategies these parameters were used. Moreover, our conclusions
are in line with the findings of Lax (above).
Since for inhomogeneous dose distributions the radiobiological effect on the tumour
cannot be fully described with only the minimum PTV dose or the mean PTV dose, the
gEUD(a) [11] was used to investigate which planning strategy results in the highest PTV dose.
The gEUD(a) weights the dose in each voxel of the PTV, the lower the selected a value, the
higher the weight of voxels with low dose, i.e. the PTV periphery. The gEUD(a) of the PTV
is on average higher for the 65% strategy than for the 80% strategy for a values of -20 and
higher. The increase for the 65% strategy is statistically significant for a-values of -10 and
higher. For a-values smaller than -20, the differences between the strategies were statistically
insignificant.
The exact value of the a-parameter for gEUD calculations of metastatic liver tumors is
unknown. Thomas et al. [13] used values of -5 and -20 as representative values for a low-grade
and an aggressive tumour respectively, for IMRT treatment plan comparison for metastatic
liver patients. By matching the expressions for the surviving fraction in the gEUD model
and the linear quadratic (LQ) model, a value for a can be estimated[14] by using the formula
a = −D(α+ 2Dβ). Under the assumption of α=0.5 Gy-1, α/β=10 Gy and a fraction dose,
D, of 12.5 Gy, the value for a is -21.9.
The colon is the site of the primary tumour for most of the liver metastases treated
with SBRT in our institute [2]. As shown by van Laarhoven et al. [15] liver metastases from
colorectal cancer contain hypoxic regions. Hypoxia leads to a decrease of the radio sensitivity
parameter α and can be incorporated in the LQ model with the oxygen enhancement ratio
(OER), which is defined as the ratio between the α under aerobic conditions and the α under
hypoxic conditions. Carlson et al. [16] give values for the OER in a range of 2.3 to 3.3 and
conclude that the OER value is nearly independent of cell type. If α decreases with a factor
of 2.8, the estimated a parameter increases to a value of -17.9 using the same assumptions as
above. Niemierko et al. [11] fitted clinical data for chordoma tumors to the gEUD model and
found a value of -13.1 for the a parameter. These considerations indicate that the true value
of the a parameter might be -20 or higher.
In clinical practice, we use a stereotactic body frame (SBF) with abdominal compression
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for reduction of respiratory tumour motion, generally resulting in a residual tumour top-to-
top motion of 0.5 cm or less (amplitude < 0.25 cm). The planning CTV to PTV margin
applied for this treatment is determined by the residual tumour motion and the set-up errors,
yielding a margin of 1.0 cm and 0.5 cm in the cranial-caudal direction and the axial directions
respectively. As shown by Wunderink et al. [17], these margins are sufficient for the applied
patient positioning method to ensure that the tumour remains inside the PTV during the whole
treatment. This means that in the equilibrium tumour position formed by the midpoint of the
respiratory cycle, the tumour is always within the PTV minus 0.25 cm margin, i.e. the PTV-
0.25. Only for a maximum set-up error and with the tumour in the maximum position of
the breathing excursion, the tumour touches the PTV surface. For 12 of the 15 patients, the
maximum distance, dmax, of the PTV voxels that receive for the 65% strategy plan a dose
lower than the minimum dose of the 80% strategy plan is smaller than 0.25 cm. This means
that in the equilibrium position of the tumour’s motion range, none of these voxels can be
covered by tumour tissue. Further, it has to be considered, that if the tumour moves to the
PTV edge (into the low dose region), the other side of the tumour wil move inwards, i.e.
towards higher doses. Since for the 65% strategy, the dose in the central part is higher than
for the 80% strategy, the effect of the low dose region on one side will be more compensated
by the central part for the 65% strategy than for the 80% strategy. N.B. this compensation
does not hold for systematic problems, e.g. in finding the isocenter coordinate.
A gEUD calculated for the total PTV volume assumes that the whole PTV is covered
with tumour uniformly. Since this is not the case for SBRT of liver metastases, a gEUD
calculation that takes into account the true variation of tumour coverage over the PTV volume
gives a better representation of the radiobiological effect to the tumour. As an approximation
to the true tumour coverage, the outer PTV shell of 0.25 cm thickness was set to zero coverage
while the rest of the PTV was set to 1 coverage resulting in the gEUDPTV-0.25. The relative
difference between the 65% strategy and the 80% strategy for the gEUDPTV was always lower
than for the gEUDPTV-0.25. The gEUDPTV-0.25(a) was on average higher for the 65% than for
the 80% strategy for each a value. The average increase was significant for a-values of -20
and higher.
In a clinical protocol, the whole patient group is generally treated with the same PTV
dose inhomogeneity. For a < -20 no statistical differences were found in gEUD(a) between
the 65% and the 80% strategy. If the tumour coverage of the PTV is taken into account, the
65% strategy results in plans with a significant higher gEUD(a) for a = -20. For a ≥ -10 the
increase in gEUD(a) for the 65% strategy is significant, irrespective of taking into account
the tumour coverage of the PTV. Since the 65% strategy is on average never worse than the
80% strategy and for the most relevant range of a-parameters better than the 80% strategy, the
65% strategy is more favourable than the 80% strategy if the whole patient group is treated
with the same PTV dose inhomogeneity. If the PTV dose inhomogeneity is individualised,
some patients may benefit from applying the 80% strategy. Another way to compare the two
planning strategies is by scaling plans of both strategies to the same gEUD(a) for a certain
value of a. In that case the dose delivered to the OAR as measured with the DIP will be lower
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for the 65% strategy than for the 80% strategy. The amount of OAR dose reduction will be
dependent on the value of the used a parameter for the gEUD(a).
4.5 Conclusion
PTV dose maximisation for SBRT of liver metastases with an inhomogeneous PTV dose pre-
scription strategy (65%) compared to a more homogeneous dose prescription strategy (80%)
leads to plans with a higher peak dose and mean dose in the PTV at the cost of small parts
with a somewhat lower dose close to the edges of the PTV. The dose in the OARs is the same
for both strategies. On average, PTV dose delivery is superior with the 65% strategy. How-
ever, apart from the isocenter dose, for each applied PTV dose parameter at least one patient
would have been better off with the 80% dose prescription strategy.
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5.1 Introduction
In stereotactic body radiation therapy (SBRT) of liver tumors, the dose is generally pre-
scribed to the 65%[1–4], or 80% isodose[5,6], closely surrounding the PTV. Treatment plans
are normally generated by a dosimetrist, applying a lengthy, trial-and-error planning proce-
dure. Currently, most patients at Erasmus MC are treated with 3×12.5 Gy, prescribed to the
65% isodose. The maximum tumour diameter is 6 cm. Treatment results are promising[2,7].
We have developed an algorithm, designated Cycle, for automated treatment plan de-
sign. Beam directions are automatically selected from a large input set of coplanar and non-
coplanar orientations (> 250), and beam shapes, sizes and weights are optimized. Gener-
ated plans do strictly adhere to imposed hard constraints for organs at risk[8–11]. In a recent
study[9], we have demonstrated that on average dose prescription to the 65% isodose is supe-
rior to prescription to 80%. However, some patients are better off with the latter.
Here, Cycle has been extended to maximize gEUDPTV(a), the generalized Equivalent
Uniform Dose for the PTV for a selected parameter a (Eq. 5.2), while not exceeding OAR
hard constraints. There are no restrictions on the minimum PTV dose. For a = -20, treatment
plans are compared to plans with optimized isocenter doses (Diso) with a surrounding 65%
or 80% isodose, and also strictly obeying the OAR constraints. In the remainder, these three
planning approaches are referred to as gEUD(-20), 65%, and 80% strategy. Other terminol-
ogy used is biological (gEUD(-20)), and conventional (65% and 80%). The hypothesis was
that, not fixing the minimum PTV dose in the gEUD(−20) strategy to a constant percentage
would generate freedom for Cycle to enhance dose delivery to the PTV, within the same im-
posed OAR hard constraints (possibly, but not necessarily approaching more closely some of
the constraint levels).
5.2 Materials and methods
5.2.1 Patients
Plan comparisons have been based on the planning CT datasets of the 15 patients also studied
in chapter 4. The imposed (clinical) OAR hard constraints were also the same (Tab. 5.1).
Structure Constraint Constraint parameter
Liver D33% < 21 Gy D33% / 15
Liver D50% or D700 CC < 15 Gy D50% / 700 CC / 15
Spinal Cord Dmax < 15 Gy Dmax / 15
Bowel, duodenum, D5 CC < 21 Gy D5CC / 21
stomach, esophagus
Heart D5CC < 21 Gy D5CC / 21
Kidney’s D33% < 15 Gy D33% / 15
Table 5.1: Applied OAR hard constraints for plan optimizations.
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5.2.2 Automatic plan generation with Cycle
Cycle has been described in detail in [8–11]. In this study, the version of [8] has been used
for plan generations with the 65% and 80% strategies (in fact the plans for the 65% and 80%
strategies are identical to those generated in chapter 4). To maximize gEUDPTV(-20) instead,
an option has been built in to replace the score function Sk(ψ,φ,w), used for selection of beam
k (Eq. 3.3), by
Sk(a= −20,ψ,φ,w) = Δ(gEUDPTV(a= −20,ψ,φ,w,k))Δ(gEUDrefPTV(a= −20,k))
×∏
j
S j,k (5.1)
The definitions are the same as in 3.A. The first term ensures that the score goes up when
gEUDPTV(-20) increases. The terms S j,k cause the score to decrease when OAR constraint
parameters j approach their imposed constraint levels. Sk(a = −20,ψ,φ,w) is zero when a
constraint level is hit.
For each patient, the set of input beam orientations (ψ,φ) was the same as in chapter
4. The allowed maximum number of selected beams was also 10. Similar to maximization
of Diso, Cycle was used in an iterative procedure with stepwise increases of the prescribed
gEUDPTV(-20), to obtain the plan with the highest possible gEUDPTV(-20), while just not
exceeding hard constraints.
5.2.3 Plan comparison
For the PTV, optimized plans were mainly compared using DPTV, min, the minimum PTV
dose, D99%, the minimum dose delivered to 99% of the PTV, and gEUDPTV(a), defined by
gEUD(a) =
(
1
N
N
∑
i=1
Dai
)1/a
(5.2)
The summation is over all N PTV voxels i with dose Di [12]. For tumors, the parameter
a is negative, but its value is uncertain. Therefore, comparisons were done for a range of
a: -100, -50, -20, -10, -5, -1. So while a=-20 was used to define the score function in the
gEUD(-20) strategy (Eq. 5.1), a range of a-values is used for comparison of the resulting
plans with the 65% and 80% strategies.
To evaluate dose delivered to OARs, the distance from the ideal plan, DIP[8,10], the DIP
taking into account only dose delivery to healthy liver, DIPliver, and the conformality index,
CI, were calculated for each plan. An ideal plan has zero dose delivery to the organs at risk.
The DIP measures how close a plan is to this situation, and is defined by,
DIP=
√√√√ M∑
j=1
C2j
M
(5.3)
M is the number of OAR constraints in the optimization. Cj is the ratio between the
actual dose/volume parameter of constraint j in the plan (e.g. the actual maximum spinal
cord dose), and its constraint level (e.g. 50 Gy). DIPliver is defined as Eq. 5.3, but contains
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only the two healthy liver parameters involved in the plan optimizations (Table 5.1). CI is
here defined as the ratio between the volume of the DPTV, 99% isodose and the total PTV
volume.
5.3 Results and Discussion
5.3.1 PTV dose evaluation
Figs. 5.1 and 5.2 show for the PTV, comparisons of gEUD(a), Dmin, D99%, Dmean, and Diso
between the gEUD(-20) approach and the 65% and 80% strategies, respectively. With the
gEUD(-20) optimisation strategy, the obtained gEUD(-20) for the PTV is up to 16.5% higher
than for the two conventional strategies. On average, the gain in gEUD(-20) is 4.5% range
[-2.0, 14.1] and 6.0%, range [-2.0, 16.5], compared to the 65% and the 80% strategy, respec-
tively.
For a ∈[-100, -5], obtained gEUD(a) values are on average highest for the gEUD(-20)
strategy. For a=-100, and a=-50 this is most pronounced when compared to the 65% strategy.
For the other a-values the mean gain in gEUD(a) is highest when compared to the 80%
strategy. The ratio Dmin/Diso is 75%, range [68, 84], 66%, range [65, 68], and 80% range
[80, 81], for the biological approach and the two conventional approaches, respectively. For
all patients, the gEUD(-20) approach yielded a higher D99% than the 65% strategy; the same
holds for most plans of the 80% strategy (Fig. 5.2). It is important to note that large inter-
patient variations are observed, especially in Fig. 5.2.
Figure 5.1: Relative differences between the gEUD(-20) and 65% strategies in the parameters
(indicated by X on the left axis) DPTV, 99%, DPTV, mean, Disoc and gEUDPTV(a) for a values
ranging from -100 to -1. The dots represents comparisons for individual patients. The line
connects patient mean values.
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Figure 5.2: Relative differences between the gEUD(-20) and 80% strategies in the parameters
(indicated by X on the left axis) DPTV, 99%, DPTV, mean, Disoc and gEUDPTV(a) for a values
ranging from -100 to -1. The dots represents comparisons for individual patients. The line
connects patient mean values.
5.3.2 Normal tissue evaluation
For the biological approach, the patient mean DIP-value is 0.263 (± 0.024). Differences with
the 65% and 80% strategies are 0.009 (± 0.015) and 0.009 (± 0.012), respectively. The mean
DIPliver for the gEUD(-20) optimized plans is 0.80 (± 0.15). Compared to the 65% and 80%
strategies, increases in DIPliver are 0.04 (± 0.06), and 0.02 (± 0.03), respectively. Observed
CI are 1.30 (± 0.09), 1.26 (± 0.08), and 1.18 (± 0.07) for the biological approach, the 65%
strategy, and the 80% strategy, respectively.
There is a tendency that dose delivery to normal tissues is somewhat increased for the
gEUD(-20) strategy, compared to both other strategies. However, since all plans do strictly
adhere to all OAR constraints (which makes them clinically acceptable), and PTV dose de-
livery is generally superior for the gEUD(-20) approach, there is an overall advantage for the
use of this strategy, rather than the 65% or 80% strategies. However, individual patients may
be better off with one of the latter two approaches.
5.4 Conclusion
An algorithm has been developed for automated treatment plan generation for liver tumors.
Beam directions are automatically selected from a large input set of coplanar and non-coplanar
orientations (> 250), and beam shapes, sizes and weights are optimized. Generated plans do
strictly adhere to imposed hard constraints for organs at risk (OAR). Using this algorithm it
has been demonstrated that on average, biological optimization is superior to conventional
strategies with a 65% or 80% isodose that closely surrounds the PTV. However, individual
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patients may benefit most from one of the latter approaches.
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Abstract
Purpose:
To investigate whether automatically optimized coplanar, or non-coplanar beam setups im-
prove IMRT treatment plans for SBRT of liver tumors, compared to an equi-angular IMRT
plan (the reference).
Methods:
For a group of 13 liver patients, an in-house developed beam selection algorithm (Cycle) was
used for generation of 3D-CRT plans with either optimized coplanar, or non-coplanar beam
setups. These 10 field, coplanar and non-coplanar setups, and an 11 field, equi-angular co-
planar reference setup were then used as input for generation of IMRT plans. For all plans,
the PTV dose was maximized in an iterative procedure by increasing the prescribed PTV dose
in small steps until further increase was prevented by constraint violation(s).
Results:
For optimized non-coplanar setups, DPTV, max increased by on average 30% (range 8 – 64
%) compared to the corresponding reference IMRT plan. Similar increases were observed
for DPTV, 99% and gEUD(a). For optimized coplanar setups, mean PTV dose increases were
only ∼4%. After re-scaling all plans to the clinically applied dose, optimized non-coplanar
configurations resulted in the best sparing of organs at risk (healthy liver, spinal cord, bowel).
Conclusion:
Compared to an equi-angular beam setup, computer optimized non-coplanar setups do result
in substantial improvements in IMRT plans for SBRT of liver tumors.
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6.1 Introduction
Stereotactic body radiation therapy (SBRT) is a promising technique for treatment of small
liver tumors with a high local control and low toxicity[1–7]. In Rotterdam, patients are treated
in a Stereotactic Body Frame (Elekta Oncology Systems, Stockholm, Sweden), using abdom-
inal compression to reduce respiratory tumor motion (generally below 5 mm, top-top[8]).
In SBRT for liver tumors, patients are mostly treated with a 3D conformal radiotherapy
(3D-CRT) technique. Generally, treatment plans consist of a large number of beams with
coplanar and non-coplanar directions, selected by a dosimetrist, and shaped with a multi-leaf
collimator [4,9–11]. Some institutes apply coplanar arcs in combination with circular collima-
tors [11]. Thomas et al. [12] showed for radiotherapy of liver tumors with conventional frac-
tionation schemes, that IMRT improves 3D-CRT treatment plans. They also found that a
standard non-coplanar beam setup improves IMRT plans, compared to a standard coplanar
setup. Tumor sizes in the latter study were much larger than the sizes normally allowed for
hypo-fractionated radiation therapy of liver tumors.
Since the tumor location inside the liver, the total liver volume, and the distance of
the tumor to other organs at risk (OAR) are rather heterogeneous among liver patients, ap-
plication of a standard setup may lead to sub-optimal solutions, compared to individualized
beam configurations. Beam selection is generally a trial-and-error procedure performed by
the dosimetrist. Liu et al. [13,14] reported on the application of an algorithm for automatic gen-
eration of geometrically optimized beam setups to determine the optimal number of beams
for SBRT of lung and liver lesions, when using a 3D-CRT dose delivery technique. Recently,
we have developed an algorithm for dosimetrical optimization of beam setups, designated
Cycle [15]. In a previous study we have demonstrated that in 3D-CRT, automatic beam angle
optimization with Cycle may significantly improve treatment plans for SBRT of liver tumors,
especially for non-coplanar setups[16]. Recently, Cycle was used to investigate differences
between prescribing dose to the 65% or the 80% isodose[17].
The purpose of this study was to investigate whether for SBRT of liver tumors, computer
optimized coplanar and non-coplanar beam setups result in better IMRT treatment plans than
an 11 equi-angular coplanar beam setup.
6.2 Methods
6.2.1 Plan generation
For 13 single metastasis patients, previously treated in our institute with SBRT, three IMRT
plans were generated, one with an optimized coplanar beam setup, one with an optimized
non-coplanar configuration, and one reference plan with 11 equi-angular coplanar beams.
IMRT plan generation with optimized beam setups was performed in two steps. First, for each
patient, the in-house developed algorithm, Cycle, was used for generation of both a coplanar
and a non-coplanar 3D-CRT plan with optimized beam directions, beam weights and beam
shapes. Second, using the beam setups of the Cycle plans, IMRT plans were generated with
the commercial XIO (CMS, Inc.) treatment planning software. Except for the constraint on
the conformality index, CI, planning constraints and objectives used in Cycle and XIO were
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identical (Table 6.1). The reference IMRT plans were also generated with XIO, again using
the same constraints and objectives.
6.2.2 Cycle for generation of a feasible beam setup
In this study, beam setups were optimized by iterative use of Cycle (next section). By itself,
Cycle only aims at generation of a feasible setup, i.e. a treatment plan with the prescribed
PTV isocenter dose, while strictly obeying all imposed constraints on PTV dose inhomogene-
ity, OARs, and other normal tissues. No explicit attempt is made to find the ’best’ treatment
plan. Generation of feasible setups has been described in detail in[15,16,18]. Here a short
summary is given. Cycle starts plan generation with an empty plan. Sequentially, new beam
directions are selected from a large set of input directions, and added to the plan.
To select a new beam, k, each beam in the set of input directions is temporarily added
to the plan (consisting of the previously selected k-1 beams). For each temporarily added
input beam direction the weight and beam shape are optimized, based on a score function.
The score function represents a trade-off between increasing the PTV dose and approaching
the imposed constraint levels, while accounting for the dose distribution resulting from the
previously selected k-1 beams. The beam direction with the highest score is added as beam k
to the plan. Further selection of beams stops if one of the following is true:
• Maximum number of allowed beam directions per plan is reached
• A constraint is violated
• The prescribed dose has been attained, i.e., plan generation was successful
In the first two situations Cycle starts a new plan generation with automatically adjusted
importance factors for the score function to better avoid approaching critical constraints.
6.2.3 Iterative use of Cycle for beam direction, shape and weight optimization
In this study, Cycle was used in an iterative procedure to automatically generate beam se-
tups with the highest possible PTV dose within all imposed constraints. Starting with the
clinical dose prescription of 3×12.5 Gy at 65% of the isocenter dose, feasible plans were
generated with stepwise increased prescribed doses, until further dose increase was prohib-
ited by unavoidable constraint violations. For the coplanar and non-coplanar plans, beams
were selected from input sets consisting of 72 or 252 orientations, respectively. The 252 in-
put beams for generation of non-coplanar plans included the 72 orientations, also used for
coplanar optimization. The maximum angle of the non-coplanar beams with the axial plane
was 30o. The maximum allowed number of beam directions per plan was 10 (N.B. a single
beam direction could be selected multiple times with different weights and beams eye view
field shapes/ penumbra margins).
6.2.4 IMRT optimization
For each of the three beam configurations per patient, XIO was used in an iterative procedure
to generate the IMRT plan with the highest possible PTV dose without violating the applied
planning constraints. As for beam setup optimization with Cycle (previous section), the
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maximum allowed PTV dose was established by stepwise increasing the prescribed dose,
while keeping the constraint levels for OAR and normal tissue constant.
In case of a constraint violation, the XIO optimization was restarted with the same
set of constraint levels, but with an increased importance factor (ranging from 2.0 to 5.0,
increases in steps of 0.5) for the violated constraint. For the maximum dose constraints,
and for the minimum PTV dose constraint a deviation of 1% volume from the constraint
level was allowed. If one of the constraints was violated while its’ importance factor had
the maximum value of 5.0, the iterative procedure was stopped, and the plan with the highest
PTV dose within the applied constraints was selected as the optimal plan. Optimal plans were
segmented using a minimum segment size of 1 × 1 cm2, and 5 discrete fluence levels.
Structure Constraint
PTV DPTV, min = 0.65 × Disoc
Liver VD> 21 Gy < 33%
Liver VD> 15 Gy < 50% or VD< 15 Gy > 700 ml
Myelum Dmax < 15 Gy
Bowel Dmax < 21 Gy
Heart Dmax < 21 Gy
Kidney VD> 15 Gy < 33%
R0 See text
R1 Dmax < DPTV, min - 5 Gy
R2 Dmax < 20 Gy
Table 6.1: Applied planning constraints for the PTV, the OAR and the non-organ-based regions
R0, R1, R2.
6.2.5 Planning constraints
Applied planning constraints are summarized in Table 6.1. For the liver DVH constraint with
a dose level of 15 Gy, one of the two volume levels is used. For patients with a normal liver
volume smaller than 1400 CC, at least 700 CC should receive a dose lower than 15 Gy[4]. For
patients with a larger normal liver volume, 50% of the volume should receive a dose lower
than 15 Gy.
R0, R1 and R2 are three non-organ based regions. R0 is all normal tissue in a 2.0 cm
margin around the PTV. R1 is all normal tissue outside R0, but inside a PTV expansion of 5.0
cm. R2 is all tissue outside the PTV expansion of 5.0 cm. The constraint on R2 was used to
avoid hot spots far away from the PTV. The constraint on R1 enforces a dose gradient between
normal tissue and the target volume. For generation of IMRT plans, a DVH constraint was
imposed on region R0 to keep the conformality index (defined as the ratio between the volume
of the prescription isodose and the PTV) lower than 1.4. The dose level of this DVH constraint
was set equal to the allowed minimum PTV dose ( = 0.65 × Disoc ), and the volume level to
(0.4 × VPTV), implying that at maximum 0.4 × VPTV of the R0 volume is allowed to receive
a dose higher than the imposed PTV dose.
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6.2.6 Plan evaluation
For comparison of PTV dose distributions of optimized plans the following parameters were
used: the minimum dose received by at least 99% of the PTV volume, DPTV, 99%, the max-
imum PTV dose, DPTV, max, and the generalized equivalent uniform doses, gEUD(-5) and
gEUD(-20) [19], calculated using
gEUD(a) =
(
1
N
N
∑
i=1
Dai
)1/a
(6.1)
For comparison of OAR dose delivery, all plans with maximized isocenter doses were
first scaled back to the clinical prescription of 3×12.5 Gy at the 65% isodose. The dose
to the liver was evaluated using the mean liver dose, Dliver, mean, and the liver volumes that
receive doses higher than 15 Gy and 21 Gy, Vliver, D>15 Gy and Vliver, D>21 Gy respectively. For
the spinal cord, bowel, and heart, the dose received by at least 1% of the volume, D1%, was
evaluated, and for the kidney’s the Vkidney, D>15 Gy (Table 6.1). The conformality index was
evaluated as the ratio between the volume of the DPTV, 99% isodose and the PTV volume.
6.3 Results
6.3.1 PTV
For each patient, PTV dose parameters for the three maximized IMRT plans are plotted in Fig.
6.1. The patient group means, and corresponding standard deviations are depicted in Fig. 6.2.
For the optimized non-coplanar beam configurations, mean increases in DPTV, max, DPTV, 99%,
gEUD(-5), and gEUD(-20) relative to the corresponding 11 field equi-angular reference setup
were 30.4% (range: 8.2% – 64.0%), 28.2% (range: 4.8% – 56.1%), 29.9% (range: 6.9% –
57.6%), 29.3% (range: 3.9% – 55.6%). Relative to the optimized coplanar setups, increases
for the optimized non-coplanar plans were 26.4% (range: -4.6% – 46.8%), 23.2% (range:
-5.4% – 40.7%), 25.4% (range: -5.7% – 44.1%), 24.1% (range: 3.6% – 41.8%). Mean
increases for optimized coplanar plans relative to reference plans were small, i.e. ∼4%.
Apart from patient 12, all four evaluated PTV dose parameters were definitely highest for the
optimized non-coplanar setup. For patient 12, the PTV was located directly next to the bowel,
which might explain the almost equal PTV doses for the three plans. N.B. the close proximity
of the bowel to the PTV in this patient prevented for all setups delivery of the prescribed dose
(3×12.5 Gy).
6.3.2 Normal tissues
OAR results after plan re-normalization to 3×12.5 Gy are presented in Fig 6.3. For the op-
timized non-coplanar IMRT plans, the average decreases in Vliver, D>15 Gy and Vliver, D>21 Gy
relative to the corresponding reference plans were considerably larger than for the optimized
coplanar plans, with values of 14.7% and 9.4%, respectively, compared to 3.3% and 2.9%.
A decrease in these parameters was observed for each patient, except for patient 12. For the
mean liver dose, improvements relative to the reference plan were similar for the coplanar
(-3.7%), and the non-coplanar (-5.4%) setups. For the optimized coplanar and non-coplanar
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Figure 6.1: Cont’d
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Figure 6.1: For each patient, PTV dose parameters, DPTV, max (a), DPTV, 99% (b), gEUD(-5) (c),
and gEUD(-20) (d).
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Figure 6.2: Patient group mean differences for the PTV dose parameters, DPTV, max,
gEUDPTV(-5), gEUDPTV(-20) and DPTV, 99% between IMRT plans with an optimized coplanar
() or non-coplanar (• ) beam setup, and the reference plan with an 11 equi-angular beam setup.
The error bars represent ±1 standard deviation variation around the population means.
setups, 11/13 and 13/13 patients showed a decrease in Dspinal cord, 1%, with population mean
decreases of 12.3% and 46.7%, respectively.
For seven patients the bowel was contoured and included in the optimizations. De-
spite the average decrease of 7.3% for the coplanar plans, only 4 of the 7 patients had a
lower Dbowel, 1% in the optimized coplanar plan compared to the reference plan. For the
non-coplanar optimization, 6 of the 7 patients presented a lower Dbowel, 1%, with an average
decrease of 21.7%. Except for patient 12, all plans had a Dbowel, 1% lower than the constraint
level of 21 Gy. For patient 12 this value is higher since for this patient the dose had to be
scaled upwards to achieve the regular clinical dose prescription level for the PTV (above). For
12/13 patients, the Vkidney, D>15 Gy was far below the constraint level of 33% with a maximum
value of 17.7%. For patient 3 the Vkidney, D> 15 Gy values were 26.4%, 28.6% and 18.2% for
the IMRT plans with respectively the reference, the optimized coplanar and the optimized
non-coplanar beam setup.
For 4 patients the heart was contoured. Compared to corresponding reference plans,
mean decreases in heart doses of 10.7% and 20.0% were observed for optimized coplanar
and non-coplanar setups, respectively. Observed population mean CI were 1.28 ± 0.09, 1.27
± 0.10, and 1.32 ± 0.08 for the reference, the optimized coplanar, and the optimized non-
coplanar beam setups, respectively.
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Figure 6.3: Patient group mean differences for the OAR dose parameters, Dliver, mean,
Vliver, D>15 Gy, liver, Vliver, D>21 Gy, Dbowel, 1% and Dspinal cord, 1% between IMRT plans with
an optimized coplanar () or non-coplanar (• ) beam setup, and the reference plan with an 11
beam equi-angular setup. The error bars represent ±1 standard deviation variation around the
population means.
6.4 Discussion
Optimized non-coplanar beam setups resulted in IMRT plans with 30% higher PTV doses
than plans for an 11 field equi-angular set-up, and 26% higher doses than for plans based on
optimized coplanar setups. The results of the present study are in agreement with the study
by Thomas et al. [12], who also observed an improvement by non-coplanar beam setups in
IMRT treatment planning for liver tumors. The target volumes in their study were consider-
able larger than in this study. Therefore, the results of the two studies are complementary,
supporting the conclusion that IMRT planning of liver tumors may be improved by applying
non-coplanar beam setups.
All Cycle generated plans included 10 different beam orientations (the maximum al-
lowed number in this study). For equi-angular beam setups in IMRT, generally an odd num-
ber is chosen to avoid opposing beams. In this study, 11 orientations were used for the
equi-angular reference setup, one more than for the optimized beam setups. Even with one
orientation less, the optimized setups performed better than the reference setup. Liu et al. [14]
investigated the optimal number of beams for SBRT of liver tumors by applying beam di-
rection optimization. They concluded that for lesions >2 cm no significant improvement is
observed if the number of beams is 9 or higher.
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In this study, plans were optimized by sequential optimization of beam orientations
(3D-CRT with Cycle), and beam intensity profiles (XIO). Especially in combination with
non-coplanar optimization in Cycle, this resulted in IMRT plans that were clearly superior to
plans generated for the reference setup. However, for 5 of the 13 patients, the plan based on
the optimized coplanar beam setup had a (slightly) lower PTV dose than the 11 field equi-
angular IMRT plan, showing that sequential optimization of angles and profiles may also
result in suboptimal IMRT plans. This emphasizes the need for integration of beam angle
and intensity profile optimization for SBRT of liver tumors. Several algorithms have been
developed for combined optimization of profiles and angles [20,21]. Since the search space
increases dramatically, approximations and simplifications are needed for staying within rea-
sonable calculation times. Currently, a research project is running in our institute, investigat-
ing integration of beam angle and beam intensity profile optimization for SBRT.
In this paper, the maximum allowed number of optimized beam directions was set to 10.
Baisden et al. [22] presented a theoretical study on the relation between the maximum tolerable
dose (MTD), which can be prescribed to the 95% of the PTV (i.e. the DPTV, 95%) without
violation of the constraints on the OARs, and the PTV and liver volume. The treatment plans
for their patients were generated for a helical TomoTherapy unit, and can be considered as
an IMRT plan with a very high number of coplanar beams. For the patient group average
volumes of the liver and the PTV in the present study, 1566 CC and 152 CC respectively,
they reported a DPTV, 95% of 60 Gy which is higher than for the plans in the present study
with an optimized coplanar beam setup (DPTV, 95% = 57 Gy), and lower than for those with
an optimized non-coplanar beam setups (DPTV, 95% = 71 Gy). Part of the increase in MTD
for their plans, compared to the IMRT plans with an optimized beam setup in this study, is
caused by the application of less strict planning constraints. In on-going studies we compare
the optimized non-coplanar 10 field setups with multi-field plans designed for treatment with
helical TomoTherapy and with the robotic CyberKnife.
6.5 Conclusion
IMRT treatment plans for SBRT of liver tumors may be considerably improved if optimized
non-coplanar beam orientations are used instead of an 11 field equi-angular setup, or an
optimized coplanar setup. IMRT cannot make up for sub-optimal beam selection.
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Abstract
Purpose:
To quantify potential benefits of CTV-to-PTV margin reduction for SBRT of liver tumours,
as allowed by enhanced treatment precision.
Methods and Materials:
For 14 patients plans were generated for the clinical margin and for 3 tighter margins. An
in-house developed algorithm was used to optimise beam directions, shapes and weights for
generation of the plan with the highest isocenter dose (Disoc), while keeping the minimum
PTV dose at least 65%×Disoc and strictly adhering to all imposed hard OAR constraints.
Each plan contains 10 optimal beam directions, automatically selected from up to 252 co-
planar and non-coplanar input directions.
Results:
Apart from the expected tumour dose escalation in Disoc, EUDPTV, and gEUDPTV) with de-
creasing margin, a simultaneous improved sparing of the normal liver (D33%, D50%, Dmean)
was also observed. The smaller the margin was, the bigger both effects. For renormalized
plans with Disoc equal to the clinical value (3×19.2 Gy), and a margin reduction of 50% (2.5
mm laterally, 5 mm longitudinally), normal liver D33% and D50% reduced on average by 22%
(maximum 38%), and 26% (maximum 47%), respectively.
Conclusions:
Using an algorithm for beam direction, shape and weight optimization, large increases in the
therapeutic ratio of liver plans could be obtained for reduced margins.
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7.1 Introduction
Stereotactic Body Radiation Therapy has been documented to provide a non-invasive treat-
ment alternative for malignant liver lesions when established curative treatment modalities
cannot be applied[1,2]. Current experience supports the perceived curative potential of this
new modality for ablative treatment of lesions in the liver with diameters ideally not exceed-
ing 5 to 6 cm[1,3–6]. A dose response relationship exists in treatment of primary and metastatic
intra-hepatic tumours, with an association between delivery of a higher dose and improved
clinical outcome[7–10]. By using stereotactic patient immobilization and set up, advanced
lesion targeting techniques, high degrees of dose conformality, and steep dose gradients, the
overall amount of normal liver tissue (liver - GTV) exposed to potentially harmful radiation
doses can be substantially reduced[1,2,11], allowing delivery of very high biologically equiva-
lent tumour doses.
At the Erasmus MC, stereotactic treatment of liver tumours is currently performed using
a stereotactic body frame (SBF, Elekta Oncology Systems, Stockholm, Sweden) for tumour
set-up, immobilization and abdominal compression, and a single slice spiral CT-scanner for
daily image guidance, achieving excellent local control rates and low toxicity[5,12]. This treat-
ment approach yields a substantial reduction in tumour motion related uncertainties, both in-
tra and inter fraction[12,13]. In a single-slice spiral CT-scanner, (residual) respiratory motion
may result in imaging artefacts, causing uncertainties in the mean position, size, and shape
of the tumour that have to be accounted for in the CTV-to-PTV margin[14,15]. Further im-
provements in the in-room imaging system are currently under examination to optimise the
therapeutic ratio of SBRT for liver tumours. A substantial increase in treatment precision will
allow the reduction of CTV-to-PTV margin[11,12,16], yielding a potential for dose escalation
and/or better protection of the surrounding healthy liver tissue. To evaluate the magnitude
of feasible target dose escalation, the impact of CTV-to-PTV margin reduction on treatment
plan quality has been investigated systematically using the planning CT-data of 14 patients,
previously treated for liver malignancies. For each patient, treatment plans were automati-
cally generated for several margin reduction protocols, with an in-house developed algorithm
for simultaneous optimisation of beam angles, weights and shapes, designated Cycle. Cycle
was used in an iterative procedure to maximally escalate the dose in the tumour centre, while
keeping the minimum PTV dose at least equal to the 65% isodose level, and strictly obeying
all normal tissue constraints. The obtained plans have an optimal balance between dose de-
livery to the tumour and sparing of normal tissues, i.e. a theoretically optimum therapeutic
ratio for each of the selected margin protocols.
7.2 Materials and Methods
7.2.1 Patients
Most of the 14 patients included in this study were previously treated with 3×12.5 Gy, always
prescribed at the 65% isodose level that closely surrounded the PTV. Patients accepted for
treatment were not eligible for surgery or RFA. The maximum lesion size was 6 cm[5].
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7.2.2 CTV-to-PTV margins
For tumour definition and treatment planning all patients had arterial and venous contrast
CT-scans, and a planning CT-scan, acquired without contrast and fully including all rele-
vant critical organs. Delineated tumours in the arterial and venous contrast CT-scans were
summed to construct the definitive CTV. The tumour delineations were assisted by MRI
scans, and reviewed by an experienced radiologist. Both on the day of treatment prepara-
tion and on treatment days, the patients were positioned in the Elekta SBF with maximum
tolerable abdominal compression to reduce respiratory tumour motion. Implanted gold fidu-
cials and fluoroscopy are used to assess residual tumour motion in all directions. For most of
the patients, the clinically applied CTV-PTV margins were 10 mm in cranio-caudal direction,
and 5 mm in antero-posterior and latero-lateral directions.
To investigate the potential benefits of margin reduction, for each patient four PTVs
were generated on the Cadplan Treatment Planning System (Varian Oncology System, Palo
Alto, CA) applying different margin protocols:
1. Protocol 0 0: 0 mm expansion in all directions, (PTV ≡ clinical CTV);
2. Protocol 0 5: 0 mm expansion in the radial (antero-posterior and latero-lateral) direc-
tions, 5 mm in the cranio-caudal direction;
3. Protocol 5 5: 5 mm expansion in all directions;
4. Protocol 5 10: 5 mm expansion in the radial directions, 10 mm in the cranio-caudal
direction (the clinically applied margin for most patients, see above).
In the remainder of this work, the protocols 1-3 are referred to as experimental protocols,
and protocol 4 as the reference protocol. The 0 0 and 0 5 protocols are not clinically feasible
as the PTV margins cannot be zero, e.g. because of set-up errors and residual uncertainty
in tumour motion and delineation. However, inclusion of these protocols does demonstrate
what is maximally possible. Moreover, using interpolation, 0 0 and 0 5 data may be used for
estimation of the impact of margins in the range 0 to 5 mm.
7.2.3 Plan generation and optimisation
For each PTV, an optimal treatment plan was generated with Cycle, an advanced, in-house
developed algorithm for computer generation of stereotactic treatment plans. The general
principles of beam orientation selection and weight optimization with Cycle, based on pre-
calculated dose distributions for a large set of coplanar and non-coplanar input beam direc-
tions (up to 252 in this study), have been described in detail by Woudstra et al. [17,18]. De
Pooter et al. have recently extended Cycle for SBRT, including field shape optimization[19].
They have demonstrated that the use of computer optimized non-coplanar beam set-ups can
significantly improve dose distributions for liver patients treated with SBRT. The latter ver-
sion of Cycle has been used in this study.
By itself Cycle is not an optimisation algorithm, as it (only) aims for generation of a
treatment plan with the prescribed tumour dose, while efficiently minimizing the approach
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of, and never exceeding, the imposed constraint levels. However, in an iterative loop, the al-
gorithmmay indeed be used to optimize a plan parameter [18,19]. In this study, for each patient-
PTV combination, a non-coplanar treatment plan was generated with the highest achievable
PTV isocenter dose, while not violating the applied hard planning constraints, as described
below. In the procedure to maximize Disoc, the isocenter dose of the clinical plan was used as
a starting point. The PTV dose was then maximized in an iterative way by repeated runs of
Cycle with successive small increases in the prescribed Disoc and keeping the Dmin constraint
at 65% of Disoc. The normal tissue planning constraints were kept constant (see next section).
The maximum number of selected beam directions per plan was set to 10. The iterative pro-
cedure was stopped if further isocenter dose increase was obstructed by constraint violation,
i.e. the next prescribed Disoc could not be obtained without a constraint violation.
7.2.4 Planning constraints
The following organ at risk (OAR) constraints were used in clinical treatment planning: for
normal liver, D33% < 21 Gy, D50% < 15 Gy; for bowel, duodenum, stomach, heart, aorta and
oesophagus D5 cc < 21 Gy; for spinal cord Dmax < 15 Gy; and for kidney D33% < 15 Gy[5].
Da% indicates that a% of the volume receives a dose of at least Da%. According to Schefter
et al. [6], at least 700 ml of normal liver should receive a total dose < 15 Gy. In this study,
when 700 ml was less than 50% of the liver, the above mentioned D50% dose constraint was
replaced by D700 ml > 15 Gy (see sections 4.2.3 and 6.2.5). From now on this constraint will
be referred to as D50% / 700 ml, where data for D50% and D700 ml have been merged together in
the patients sample. All other OAR constraints are the same as the clinical constraints.
For the automatic plan generations in this study, apart from the OAR constraints, two
additional regions were defined in the normal tissue by expansions of the PTV (expansion 1
is the PTV plus a 2.0 cm margin, expansion 2 the PTV plus a 5.0 cm margin). Region R1
includes all tissue outside expansion 1 and inside expansion 2. Region R2 is all tissue outside
expansion 2. For each region a maximum dose constraint was imposed. The constraint on
R1 aims at conformality of the dose distribution to the target volume, while the constraint
on R2 avoids hot spots and limits dose delivery far away from the target volume. The value
for the constraint on R1 was always chosen 5 Gy lower than the desired minimum PTV dose
(Dmin) level. For R2, a maximum dose constraint of 20 Gy was used for each patient. In each
plan generation process the constraints were considered hard constraints, i.e. for no reason
constraint violations were allowed (see previous section).
7.2.5 Plan evaluation
The impact of the three experimental margin protocols on treatment plan quality was first
investigated by comparing the achieved escalated tumour doses with the maximised dose for
the reference protocol, as a primary endpoint, and dose delivery to the adjacent healthy liver
(within constraints) as a secondary endpoint. The optimised 3D dose distributions were then
rescaled to the same prescription dose (3×12.5 Gy at the 65% isodose level), in order to
evaluate the potential gain in liver sparing as a primary end point.
For evaluation of PTV dose distributions, Disoc, the Equivalent Uniform Dose (EUD),
and the generalized EUD (gEUD) were applied[9,20]. EUD was calculated according to the
96 Chapter 7
expression which takes into account the fractionation effect, with SF2 (Surviving Fraction
after 2 Gy irradiation) equal to 0.5[21]. The gEUD was calculated according to Niemierko et
al. [22], with a = -20. [19,23]
The D33% and D50% / 700 ml values for healthy liver were used for the automatic plan
generations in this study. Apart from these DVH parameters, the effective dose (Deff) [24–26]
and the fraction damaged (fdam) [27,28] were used for liver exposure evaluations. A wide range
of values for the volume parameter n has been reported in the literature [29–32] for hepatic
Deff calculation, according to the Lyman Kutcher Burman NTCP model. The values 0.26,
0.52, 0.97, and 1 (Deff(n = 1) = Dmean) were used in the analysis presented as follow. For
what concerns fdam evaluation, the critical volume NTCP model has been applied with k =
1.95 and D1/2 = 41.2 Gy, as estimated by Jackson et al. [33]. For the calculations of Deff(n)
and fdam, the physical 3D dose distributions were first converted into Normalized Total Dose
(NTD) distributions, using the linear quadratic model with an α/β ratio of 2 Gy[34].
7.3 Results
7.3.1 Dose escalation
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Figure 7.1: Dose Escalation Histogram: fraction of patients that experienced a dose escala-
tion equal or higher than the respective x value. The experimental 0 0, 0 5, 5 5 protocols are
compared with the reference 5 10 protocol.
Per definition, a PTV includes normal tissue regions to account for tumour motion and
set-up uncertainties. The smaller the margins, the less normal tissue is included in the high
dose region. For a correctly implemented optimisation algorithm, the isocenter dose should
therefore always increase, as a function of margin decrease. This result was confirmed, as
shown by the cumulative distributions of dose escalation, for the 0 0, 0 5 and 5 5 protocols,
plotted in Fig. 7.1. For each experimental margin, 100% of the patients (14), had a positive
dose escalation. Escalated PTV dose increases with decreasing CTV-to-PTVmargin. Fig. 7.1
shows that 50% of the patients experienced a dose escalation higher than 31%, 19% and 12%
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Figure 7.2: Relative changes in PTV volume (Vol), PTV isocenter dose (Disoc), normal liver
D33% and D50% / 700 ml, for the 0 0 (a), 0 5 (b), 5 5 (c) protocols compared to the reference 5 10
protocol, for 14 patients.
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for the 0 0, 0 5 and 5 5 protocols, respectively. For each patient and margin, the reduction in
PTV volume, the escalated Disoc, and the corresponding changes in the D33% and D50% / 700 ml
liver values are plotted in Fig. 7.2. The EUD and gEUD dose escalations, as shown in Fig.
7.3, were not statistically different from the increases in Disoc.
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Figure 7.3: Population mean differences (%) for the escalated PTV isocenter dose (Disoc), and
corresponding changes in PTV EUD and gEUD, and normal liver D33% and D50% / 700 ml values,
as a function of the applied margin protocol, and compared to the reference 5 10 protocol. The
error bars represent ± 1 SD for the mean values. All the reported differences are statistically
significant, according to the applied t-test (p < 0.03).
As mentioned above, the increase in Disoc for each patient was expected. On the other
hand, it is interesting to note that for most patients, the PTV dose escalation was accompanied
with a simultaneous decrease in the liver D33% and D50% / 700 ml values (Fig. 7.2). Also mean
relative differences in both parameters are significantly below zero (Fig. 7.3). After all, the
aim of the optimisation was to maximally increase the PTV dose while just not violating any
of the normal tissue constraints, with no effort in actually reducing the dose to the OARs.
Fig. 7.4 summarizes the impact of the dose escalations on all normal liver parameters
used in this study (section 7.2.5). In a relative comparison with the reference margin proto-
col, all experimental protocols have a statistically significant lower fdam, consistent with the
findings for D33% and D50% / 700 ml. Also, each of these three parameters shows a gain in liver
sparing with decreasing margin. The balance between the counter-acting effects of increasing
liver doses, and reducing the amount of normal liver tissue inside the PTV (high dose region),
is well expressed by the behaviour of Deff(n). For all values of n, an overall increasing gain
with margin reduction is still evident. However, depending on the applied margin and volume
parameter, n, the reduction in Deff may become small, and statistically insignificant, making
dose escalation with a concurrent sparing of the liver not always possible.
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Figure 7.4: Population mean differences (%) of normal liver Dmean, Deff(0.26, 0.52, 0.97), fdam
and D33%, D50% / 700 ml, between the experimental protocols and the 5 10 reference protocol.
The error bars represent ± 1 SD for the mean values, the numbers are p-values, calculated with
a t-test, for statistically significant (p < 0.05) differences.
7.3.2 Normal liver sparing
With the applied dose escalation procedure, the dose delivered to OARs is iteratively re-
distributed such that the highest possible Disoc is obtained without exceeding any of the con-
straints. In this way, plans are generated with an optimal therapeutic ratio. The impact
of reduced PTV margins on the dose delivery to OARs was studied systematically by re-
normalising all optimised dose escalated plans to 3 × 12.5 Gy at the 65% isodose. Being the
liver the major cause of complications in SBRT for intra-hepatic malignancies, the attention
was again focused on normal liver sparing. The data obtained for D33%, D50% / 700 ml and
Dmean are presented in Fig 7.5. All three dose parameters show a large decrease, proportional
to the reduction in margins.
7.4 Discussion
As far as we know, this is the first systematic study on the dosimetric impact of selected
PTV margins in SBRT of liver tumours. Using commonly applied indicators for the risk
of normal tissue damage, it has been demonstrated that reduction of CTV-to-PTV margins
allows substantial target dose escalation for all studied patients. For each patient, the allowed
target dose increase depends on the extent of the margin reduction. The observed potential
for dose escalation is in agreement with previous investigations conducted on the effects
of breathing margin reduction in conformal radiotherapy of liver and lung tumours[35–37].
Moreover, in our work, for all plan generations with reduced margins, the beam set-ups were
optimised independently from the geometry of the clinical treatment beams, using an in-
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Figure 7.5: Population mean differences (%) in normal liver D33%, D50% / 700 ml, and Dmean
as a function of the applied margin protocol, compared to the reference 5 10 protocol. The
involved optimized plans were all normalized at 3×12.5Gy @65%. The error bars represent ±
1 SD for the mean values. All the reported differences are statistically significant, according to
the applied t-test (p <0.001).
house developed plan optimisation algorithm. This approach gives more degrees of freedom
to optimally take advantage of the reduction in target volume, without limitations in the beam
configuration, except for the maximum allowed number of beam directions (10 in this case).
The importance of beam angle optimization for SBRT of liver tumours has recently been
demonstrated by de Pooter et al. [19].
For each patient in the study, an escalation in Disoc was possible in each of the three
experimental margin protocols. The larger the margin reduction, the higher was the allowed
increase in Disoc. Percentage increases in the single point parameter Disoc translated in almost
equal increases in PTV EUD and gEUD, the latter two taking into account the full 3D dose
distribution of the PTV. This is probably due to the minimum PTV dose constraint applied in
the optimisation process (Dmin ≥ 65% × Disoc), resulting in a high similarity in the obtained
PTV dose distributions. Mean PTV dose increases were 30%, 19%, and 13%, respectively,
for the 0 0, 0 5, and 5 5 protocols. Interpolation in Figure 7.3 shows that for a 50% mar-
gin reduction in all directions (2.5 5 protocol), the obtained mean dose escalation is 16%
(maximum increase 27%). While increases in Disoc, and PTV EUD and gEUD as a function
of margin reduction were to be expected, the concurrent statistically significant average de-
creases in the normal liver parameters D33%, D50% / 700 ml, for all protocols, were not foreseen.
In fact, the optimisation process was carried out with the hard condition of not exceeding the
clinically applied constraints, without any attempt to reduce dose to normal tissues. Obvi-
ously, for these parameters, the positive effect of decreasing the amount of normal liver tissue
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inside the high dose region surrounding the CTV, by reducing the CTV-to-PTV margin, was
higher than the negative effect of liver dose increase caused by PTV dose escalation.
Due to the present lack of statistics and follow up time, there’s still no validated radio-
biological model to predict normal tissue complication for hypofractionated stereotactic treat-
ment of lesions in the liver. One of the main issues to be addressed is the influence of the
fractionation schedule (very high doses-few fractions) on the underlying damage (and repair)
mechanisms and the related biological endpoints. Deff and fdam represent the core quantities
of the NTCP models most frequently used to predict healthy liver complication probabil-
ity for conventional radiotherapy. The role of these parameters, as applied here, is intended
as an estimation of the trend of relative variation, in comparison with the dosimetric DVH
quantities D33% and D50% / 700 ml.
For the three applied margin protocols, no evidence was found of a correlation between
tumour and liver size and the magnitude of PTV dose escalation and normal liver sparing.
The analysis was carried out, for each patient individually, as a relative comparison between
different protocols; whereas, to evaluate the role of target (and liver) volume in the whole
population, patients heterogeneity, in particular for what concerns tumour position relative to
the OARs, should be considered.
Specific attention was paid to possibilities for dose escalation with the 5 5 protocol after
clinical implementation of a new multi-slice CT-scanner, involving a significant reduction in
image artefacts due to target motion, both in the planning CT and in the treatment CT-scans,
and a consequent decrease in target position and dimension uncertainties [12,14,16]. As men-
tioned above, this protocol resulted in a mean dose escalation of 13% (maximum increase
25%). The results also showed that 100% (14), 57% (8) and 43% (6) of the patients were
suitable for a 3 × 15, 3 × 17.5 and 3 × 20 Gy (65% isodose) fractionation protocol, respec-
tively, without violation of any of the clinical constraints. Only in three of fourteen cases, the
liver constraints limited an escalation to 17.5 and 20 Gy. Depending on the severity of the
violation and the importance of the related OAR complication, a single patient risk-benefit
evaluation should be made between the potential improvement in tumour control and the
higher risk for normal tissues [38].
With abdominal compression in a SBF, respiratory tumour motion can generally be lim-
ited to 0.5 cm (cranio-caudal direction, top-top amplitude). Recently, we have demonstrated
that when using a single-slice spiral CT-scanner, motion artefacts in the 3D planning CT-scan
and the daily 3D treatment CT-scans, caused by the residual motion, give rise to substantial
target volume increases, together with the amount of uninvolved tissue irradiated[12,16]. It is
well known that also 4D CT scans may exhibit artefacts. Future clinical studies on motion
artefacts in 4D CT scans of patients treated with abdominal compression in a SBF are needed
to assess the allowed margin reduction with daily 4D CT guidance.
In this study plans were generated with an optimal therapeutic ratio; the gain in this ratio
might be used for dose escalation (above), or to maximally spare the OARs. The magnitude
of the potential for OARs sparing (in particular the liver) was studied by renormalizing all
maximally escalated plans to the clinical prescription, i.e. 3 × 12.5 Gy at the 65% isodose
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surrounding the PTV. Even with the small margin reduction of the 5 5 protocol, decreases in
mean D33% and D50% / 700 ml as high as (19±2)%, and (20±4)%, respectively, were obtained.
Interpolation in Figure 7.5 shows that for the 2.5 5 protocol D33% and D50% go down by on
average 22% (maximum 38%), and 26% (maximum 47%), respectively.
7.5 Conclusions
Implications of margin reduction for tumour dose escalation and OAR sparing have been
systematically investigated with an in-house developed algorithm (Cycle) for generation of
stereotactic plans, with optimised coplanar and non-coplanar beam orientations, weights and
shapes. Apart from the expected tumour dose escalation, margin reduction also allowed a
(concurrent) substantially improved sparing of healthy liver tissue, as evidenced by dosimet-
ric quantities variations in agreement with common predictors of liver toxicity occurrence.
Bibliography
[1] Fuss M, Thomas Jr. CR. Stereotactic body radiation therapy: an ablative treatment option for
primary and secondary liver tumors Ann Surg Oncol. 2004;11:130–138.
[2] Kavanagh BD, Timmerman RD, eds. Stereotactic Body Radiation Therapy, Lippincott, Williams,
and Wilkins, Baltimore, MD 2005.
[3] Dawson LA, Hawkins M, Eccles C, et al. Phase I study of stereotactic radiotherapy for unresectable
primary and metastatic liver cancer Radiother Oncol. 2006;80:S19–S20.
[4] Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors:
results of a phase I/II trial J Clin Oncol. 2001;19:164–170.
[5] Me´ndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for pri-
mary and metastatic liver tumors: A single institution phase I-II study Acta Oncol. 2006;45:831–
837.
[6] Schefter TE, Kavanagh BD, Timmerman RD, et al. A phase I trial of stereotactic body radiation
therapy (SBRT) for liver metastases Int J Radiat Oncol Biol Phys. 2005;62:1371–1378.
[7] Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent
hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol.
2000;18:2210–2218.
[8] Kavanagh BD, Zaemisch R, Schefter TE, et al. The Influence of Dose and Tumor Volume on
Local Control Following Stereotactic Body Radiation Therapy Int J Radiat Oncol Biol Phys.
2005;63:S480.
[9] McCammon R, Schefter TE, Zaemisch R, et al. Improved Local Control Associated With Dose-
Escalated Stereotactic Body Radiation Therapy (SBRT) Indicates Dose-Response Relationship Int
J Radiat Oncol Biol Phys. 2007;69:S152:S153.
[10] Park W, Lim DH, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular
carcinoma Int J Radiat Oncol Biol Phys. 2005;61:1143–1150.
Chapter 7 103
[11] Dawson LA. Improving inter- and intra-fraction reproducibility Radiother Oncol. 2006;78:S15–
S16.
[12] Wunderink W, Me´ndez Romero A, Vasquez Osorio EM, et al. Target coverage in image-guided
stereotactic body radiotherapy of liver tumors Int J Radiat Oncol Biol Phys. 2007;68:282–290.
[13] Wulf J, Hadinger U, Oppitz U, et al. Stereotactic radiotherapy of extracranial targets: CT-
simulation and accuracy of treatment in the stereotactic body frame. Radiother Oncol.
2000;57:225–236.
[14] Balter JM, Ten Haken RK, Lawrence TS, et al. Uncertainties in CT-based radiation therapy treat-
ment planning associated with patient breathing Int J Radiat Oncol Biol Phys. 1996;36:167–174.
[15] Chen GT, Kung JH, Beaudette KP. Artifacts in computed tomography scanning of moving objects
Semin Radiat Oncol.. 2004;14:19–26.
[16] Xi M, Liu MZ, Deng XW, et al. Defining internal target volume (ITV) for hepatocellular carcinoma
using four-dimensional CT. Radiother Oncol. 2007;84:272–278.
[17] Woudstra E, Storchi PR. Constrained treatment planning using sequential beam selection Phys Med
Biol. 2000;45:2133–2149.
[18] Woudstra E, Heijmen BJM. Automated beam angle and weight selection in radiotherapy treatment
planning applied to pancreas tumors Int J Radiat Oncol Biol Phys. 2003;56:878–888.
[19] de Pooter JA, Me´ndez Romero A, Jansen WP, et al. Computer optimization of noncoplanar beam
setups improves stereotactic treatment of liver tumors Int J Radiat Oncol Biol Phys. 2006;66:913–
922.
[20] Kavanagh BD, Timmerman RD, Benedict SH, et al. How should we describe the radiobiologic
effect of extracranial stereotactic radiosurgery: equivalent uniform dose or tumor control probabil-
ity? Med Phys. 2003;30:321–324.
[21] Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose
Med Phys. 1997;24:103–110.
[22] Niemierko A. A generalized concept of equivalent uniform dose (EUD)Med Phys. 1999;26:1100.
[23] Thomas E, Chapet O, Kessler ML, et al. Benefit of using biologic parameters (EUD and
NTCP) in IMRT optimization for treatment of intrahepatic tumors Int J Radiat Oncol Biol Phys.
2005;62:571–578.
[24] Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal
tissue irradiation: the effective volume method Int J Radiat Oncol Biol Phys. 1989;16:1623–1630.
[25] Lyman JT. Complication probability as assessed from dose-volume histograms Radiat Res Suppl.
1985;8:S13–S19.
[26] Lyman JT, Wolbarst AB. Optimization of radiation therapy, III: A method of assessing complica-
tion probabilities from dose-volume histograms Int J Radiat Oncol Biol Phys. 1987;13:103–109.
[27] Jackson A, Kutcher GJ, Yorke ED. Probability of radiation-induced complications for normal tis-
sues with parallel architecture subject to non-uniform irradiation.Med Phys. 1993;20:613–625.
[28] Niemierko A, Goitein M. Modeling of normal tissue response to radiation: the critical volume
model. Int J Radiat Oncol Biol Phys. 1993;25:135–145.
104 Chapter 7
[29] Cheng JC, Wu JK, Lee PC, et al. Biologic susceptibility of hepatocellular carcinoma pa-
tients treated with radiotherapy to radiation-induced liver disease Int J Radiat Oncol Biol Phys.
2004;60:1502–1509.
[30] Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the
Lyman NTCP model Int J Radiat Oncol Biol Phys. 2002;53:810–821.
[31] Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation Semin Radiat Oncol.
2005;15:279–283.
[32] Xu ZY, Liang SX, Zhu J, et al. Prediction of radiation-induced liver disease by Lyman normal-
tissue complication probability model in three-dimensional conformal radiation therapy for pri-
mary liver carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:189–195.
[33] Jackson A, Ten Haken RK, Robertson JM, et al. Analysis of clinical complication data for radiation
hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys. 1995;31:883–891.
[34] Trott KR and Herrmann T. Radiation effects on abdominal organs. In: Scherer E, Streffer C, Trott
KR, eds. Radiopathology of organs and tissues:329–338, New York: Springer 1991.
[35] Engelsman M, Remeijer P, van Herk M, et al. Field size reduction enables iso-NTCP escala-
tion of tumor control probability forirradiation of lung tumors. Int J Radiat Oncol Biol Phys.
2001;51:1290–1298.
[36] Nelson C, Starkschall G, Chang JY. The potential for dose escalation in lung cancer as a result of
systematically reducing margins used to generate planning target volume Int J Radiat Oncol Biol
Phys. 2006;65:573–586.
[37] Ten Haken RK, Balter JM,Marsh LH, et al. Potential benefits of eliminating planning target volume
expansions for patient breathing in the treatment of liver tumors Int J Radiat Oncol Biol Phys.
1997;38:613–617.
[38] Dawson LA. Individualizing and adapting treatment delivery: the liver model Radiother Oncol.
2006;78:S27.


Chapter 8
General discussion
108 Chapter 8
8.1 Introduction
In stereotactic radiotherapy the total dose is delivered in a low number of fractions. This
increases the biological effectiveness for eradication of tumors (e.g. 60 Gy in 3 fractions
of 20 Gy may be equivalent to 150 Gy delivered in fractions of 2 Gy). Due to the high
effective dose, the local control of stereotactic radiotherapy for metastatic liver patients is
better than for radiotherapy using conventional fractionation schemes[1,2]. Because of the
low number of fractions, the biological damage to surrounding healthy tissues might also
increase, potentially leading to more toxicity. To prevent this, improved treatment technology
and treatment planning are necessary for better avoidance of dose delivery to involved organs
at risk (OAR).
This thesis discusses several techniques for more focused stereotactic irradiation of
intra-cranial (chapter 2) and extra-cranial (liver) tumors (chapters 3 to 7). In the remainder
of this chapter, issues related to further improvement of treatment planning for stereotactic
radiotherapy are discussed. The automated beam direction selection algorithm, Cycle, was
successfully applied for treatment planning of SBRT of liver tumors. In section 8.2, possibil-
ities to implement Cycle for automated selection and optimization of stereotactic arc therapy
for intra-cranial lesions are discussed. The clinical value of automated beam direction opti-
mization was demonstrated in chapters 3 and 6. Technical issues related to clinical imple-
mentation of Cycle, and clinical issues related to improved treatment planning for SBRT are
discussed in sections 8.3 and 8.4, respectively. In chapters 3 and 6, the value of non-coplanar
treatment planning was proven for respectively 3D-CRT and IMRT. A discrepancy suggested
in the quantitative results of both chapters, is further discussed in section 8.5.
8.2 Cycle for treatment plan optimization in stereotactic arc radiotherapy for
intra-cranial lesions
Selection of arcs and their weights in stereotactic arc therapy for intra-cranial lesions is
largely based on beams eye views (BEV). Arcs having BEV field projections with small
overlaps with OARs are generally preferred. Arcs with a uniform angular distribution con-
tribute to the conformality of the prescription isodose to the PTV. In a study by Lu et al. [3],
it was shown that automatic optimization of stereotactic arc therapy improvises the treatment
planning. Since the search space is large, full dosimetrical optimization becomes very com-
putation intensive. In the study by Lu et al. [3] this was anticipated by first selecting a set
of arcs based on BEV images, and in a second step applying a dosimetrical optimization of
these arcs. Cycle has shown to be an efficient algorithm in terms of computer power for op-
timization problems with a large number of degrees of freedom. It might also be possible to
extend it for improved treatment planning of stereotactic arc treatments.
A way to do this could be to treat arcs in the same way as beams in the current approach
(Fig. 3.1), meaning that Cycle sequentially selects the arcs from a large initial set of pre-
calculated arcs. Each entry in the initial set is characterized by a start and stop gantry angle,
and a couch angle. These angles have discrete values with an equal separation between
neighboring angles. The structure of the sequential selection loop, and the score function
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in the Cycle algorithm stay the same, see Fig. 3.1 and section 3.2.2. This means that for
selection of arc k, each arc from the initial set is temporarily added to the plan consisting of
the previous selected k-1 arcs. The weight of each temporarily added arc is optimized based
on the score function. The arc with the highest score is selected and added to the plan. The
same stop criteria might be used as for selection of beam directions in the current approach
(section 3.2.2).
For pre-calculation of a dose distribution of an arc in the initial set, the dose distributions
of a discrete set of individual beams, separated equi-angularly between the start and stop
gantry angles, have to be summed. An angle separation of 10o between the individual beams
results in sufficient accurate calculation of dose distributions[4]. Since a beam direction can
be used in multiple arcs, the dose distributions of all the required beams have to be calculated
before starting calculation of the dose distributions of the arcs in the initial set.
For 10o separations in both the couch and the gantry (start and stop) angles, the total
number of arcs in the initial set can be up to 22000. Due to this large number of arcs in the
initial set, the computation time will be high. This might be resolved by parallel computing,
see section 8.3.2. Other solutions are to constrain the lengths of arcs with a minimum and
maximum limit. For stereotactic arc therapy with cone shaped collimators, beam shape opti-
mization in Cycle treatment planning is not needed, since proper cone diameters have to be
selected in advance. For dynamic arc therapy using a multi-leaf collimator to continuously
adjust the beam shape according to the PTV BEV projection, automated arc selection has to
include beam shape optimization.
8.3 Technical issues related to clinical application of Cycle for liver SBRT
8.3.1 Introduction
This thesis presents investigations on increasing the therapeutic ratio for liver cancer treat-
ment by improved treatment planning techniques. Although the current liver SBRT treatment
has an acceptable toxicity and high local control [1], further increase of the therapeutic ratio
by clinical introduction of the proposed technical developments is still beneficial;
• Current toxicity is acceptable, but not negligible, especially for HCC patients [1]. Im-
portant reductions are still desired.
• Despite the high actuarial two-year local control rates of 86% for metastases and
75% for HCC tumors [1], there remains room for improvement, which probably can
be achieved by escalation of the PTV dose. Recently, higher PTV doses were allowed
for patients with liver metastases. Because of the observed toxicity in our own HCC
patient group[1], and reported toxicities in the literature[5,6], the PTV dose for these
patients was not increased, despite the lower control rate.
• The median follow-up of the patient group is short, and a decrease in local control can-
not be ruled out. In that case, increase of the therapeutic ratio allows for escalation of
the PTV dose for new patients, without or with a small increase in OAR dose. Patients
with a relapse might be safely re-treated.
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• Currently, only lesions with a diameter smaller than 6 cm are treated. Increase of
this limit will unavoidably lead to larger PTVs and, without improved techniques, also
to increased volumes of normal tissue and OARs irradiated with a high dose. With
improved technology, larger tumors might be treated, while avoiding a higher chance
on toxicity.
• In the current treatment protocol, patients with more than 3 lesions are not eligible for
treatment. Dose to the normal tissues, and in particular to the liver, will increase with
the number of lesions to be treated. By introducing new techniques to better spare
healthy tissues, patients with a higher number of lesions might also be treated, while
still not increasing toxicity.
The current Cycle algorithm has been mainly used for research purposes. Clinical treat-
ment planning was performed with Cycle for some difficult clinical cases, by manually im-
porting the Cycle selected beam angles and weights into the clinical treatment planning sys-
tem. For more large-scale clinical use of Cycle, a number of important technical issues are
addressed in this section, such as calculation time, dose calculation engine and the feasibility
of beam directions in the initial set. In the last two paragraphs, future technical developments
are discussed; integration of Cycle with IMRT, and 4D planning with Cycle.
8.3.2 CPU time for plan optimization with Cycle
Computer generation of optimal plans with Cycle is almost fully automated. Only a few steps
do still involve operator time, but with a few straightforward software changes, involvement
of operators can be fully avoided. For the Cycle planning procedure described in chapter 6
the total calculation time was around 10 hours on an Intel Xeon 3.2 GHz single processor
workstation. Optimized plans have the best value of a selected plan parameter (e.g. tumor
dose), while strictly adhering to applied constraints. For generation of the plan with the most
favorable plan parameter value (highest minimum PTV dose in section 3.2.5, or highest max-
imum PTV dose in section 6.2.3), the prescription for the involved parameter was gradually
changed with fixed, small steps, each time followed by a new plan generation with Cycle.
The convergence speed of this procedure can probably be increased substantially by allowing
bigger prescription changes if for the previous prescription a plan could easily be attained.
In each iteration step, the plan generation is based on sequential selection of treatment
beams, and each selection involves temporary addition of all (250) input beams to the plan for
optimization of the corresponding weight and shape, using a score function. The latter pro-
cess mainly determines the computation time per iteration step. Currently, these temporary
additions and optimizations are performed sequentially with a single processor workstation.
However, this process can easily be parallelized using a cluster of PCs with a high number of
nodes. The input beams are then distributed among the nodes of such a cluster for weight and
shape optimizations. In this way, the calculation time will decrease at maximum with a factor
equal to the number of nodes. The actual decrease will be somewhat lower due to CPU time
required for collection of the optimization results of the satellite nodes on the central node. If
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10 or more nodes are used, the total calculation time for a non-coplanar optimized plan can
be reduced to one hour or less.
8.3.3 Clinically feasible beam directions
The initial set of non-coplanar beam directions for plan optimization with Cycle used in
chapters 3-7 was composed of beams uniformly distributed between the maximum upper and
lower angles with the axial plane (Fig. 3.2), αup and αlow. The applied αup and αlow were
constrained by the limitation that none of the beams may intersect the upper or lower CT-slice
(see section 3.2.4).
Possibly, there are beams in these sets, which are not feasible to deliver in clinical prac-
tice because of collision with treatment couch or other equipment. Therefore, the presented
increases in plan quality for treatment planning with non-coplanar beams instead of coplanar
beams in chapter 3 and 6, might in some cases be an overestimation of the practically achiev-
able increase.
On the other hand, the scan lengths of the applied planning CT scans were relatively
small, as the scans were initially not intended for generation of optimized non-coplanar plans.
Consequently, for most patients, the allowed αup and αlow (Tab. 3.2), restricted possibilities
for generation of optimal non-coplanar plans. Therefore, the presented improvement of treat-
ment planning with non-coplanar beams can be an underestimation of what can be achieved
in clinical practice.
Currently, the number of planning CT slices for liver SBRT patients is increased to allow
beams with larger α angles. Furthermore, treatment couches are being developed that are
controlled with a robotic arm, yielding a larger collision free area, and thereby allowing for
a larger set of allowed non-coplanar beams. Both developments have the potential to further
enhance advantages of non-coplanar beam set-ups for SBRT of liver patients, compared to
coplanar treatments.
8.3.4 Dose calculation engine
Optimization with Cycle is based on pre-calculated dose distributions for all beams in the
initial set (section 3.2.4). In the current version of Cycle, a pencil beam algorithm is used for
pre-calculation of these dose distributions, which is sufficiently accurate for dose calculation
of liver treatment plans. The dose in each voxel is calculated as the product of the off-axis
dose and the depth dose. The off-axis dose is calculated with a 2D-convolution of pencil
beams. Connecting Cycle with an external dose calculation engine using a more advanced
algorithm, such as collapsed cone or even Monte Carlo, for pre-calculating dose distributions
can easily be accomplished. For treatment planning of lung tumors these advanced algorithms
are necessary to avoid loss of accuracy in dose calculation[7].
For beam shape optimization in Cycle, the off-axis dose has to be re-calculated after
each change of the beam shape (see section 3.2.3). In the current Cycle version, these re-
calculation steps use half of the total calculation time for generation of a treatment plan.
When introducing more advanced dose calculations methods, care should be taken to avoid
further increase of CPU time needed for beam shape optimization.
In each step of the beam shape optimization routine only a small number of pencil
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beams close to the field edge is switched on or off. Instead of doing a complete re-calculation
in each step, a much faster method is to add/remove the dose contribution of each pencil
that is switched on/off for each voxel. For this purpose, the dose contribution in voxel i
from pencil beam j for each pencil close to the edge of the field could be stored during the
pre-calculation of dose distributions for beams in the initial set.
8.3.5 Simultaneous beam direction and profile optimization
In chapter 6, the importance of non-coplanar beam setup optimization for IMRT in SBRT of
liver tumors was demonstrated. The IMRT plans were optimized in a sequential procedure
by first using Cycle to generate optimal beam angles for a 3D CRT plan, and then enter these
angles into a commercial TPS (XIO, CMS) to generate intensity profiles for an optimal IMRT
plan. In this study, for each patient, IMRT plans were generated for both a coplanar and a
non-coplanar beam set-up, optimized with Cycle. The two IMRT plans with optimized beam
orientations were compared with an IMRT plan for a coplanar, 11 field equi-angular setup.
Compared to the latter set-up, optimized non-coplanar set-ups yielded much larger maximum
PTV doses (∼30%), while strictly staying within the imposed constraints. Possibly, even
higher dose escalations could have been obtained if non-coplanar beam angle optimization
and beam profile optimization would have been performed simultaneously, and not sequen-
tially. An indication for suboptimal performance of sequential optimization steps is the obser-
vation that for a few patients, IMRT plans based on Cycle optimized coplanar beam set-ups
performed (slightly) worse than corresponding plans generated for the 11 field equi-angular
setup. In a study by Woudstra et al. [8], it was shown that Cycle integrated with segmented
IMRT (i.e., only the intensity in a few pre-defined segments could be modulated) improved
treatment planning for esophagus tumors. The IMRT implementation in that study[8] did not
include beam shape optimization, which is important for stereotactic treatment.
Currently, Cycle is extended with a new algorithm for segmented IMRT that will in-
clude beam segment shape optimization. Planning comparisons will be performed to test the
hypothesis that simultaneous optimization of beam angles and profiles will further improve
plan quality. In another project in Erasmus MC, beam angle optimization will be combined
with a more advanced algorithm for profile optimization. Again, planning comparisons are
needed to assess the relative quality of the generated plans.
8.3.6 4D planning with Cycle
Currently, treatment planning is performed on a static 3D-CT data set, and a PTV is con-
structed to avoid local underdosage of the CTV resulting from residual breathing motion of
the CTV and tumor set-up errors. The advent of 4D-CT imaging allows for a more accurate
prediction of the position and shape of OARs and CTV as a function of the breathing cycle
phase during treatment. The clinical introduction of 4D-CT may result in smaller CTV-PTV
margins [9,10].
On the other hand, a 4D CT data set, consisting of n 3D-CT data sets corresponding to n
phases in the breathing cycle, may also be directly used for plan generation in order to include
simulated respiratory motion in the optimization process (4D treatment planning) [11,12]. The
advantage of 4D planning is that the CTV can be used as planning target instead of the
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PTV, potentially leading to a smaller volume of normal tissue receiving a high dose[12]. As
explained below, Cycle may be extended with an option for 4D planning.
As for each 4D planning algorithm, a basic requirement for plan generation is access to
a patient specific co-registration matrix, determined with rigid or non-rigid registration[13,14],
containing for each voxel in each structure (OAR or target) the position in each phase of the
breathing cycle. To allow 4D planning with Cycle, for each beam angle in the initial set,
separate dose distributions have to be pre-calculated for each of the n CT-scans and added
using the co-registration matrix and the relative weights of the n phases. If beam shape
optimization is not required, the current version of Cycle can then be used to generate a 4D
treatment plan based on the composite pre-calculated dose distributions.
To include beam shape optimization in 4D planning, Cycle has to be modified to allow
calculation of off-axis dose distributions for modified field shapes, for n 3D-CT data sets in-
stead of the current single 3D-CT data set. Moreover, dose addition using the co-registration
matrix must be repeatedly performed during the optimization process. As a consequence,
the calculation time for beam shape optimization might increase by a factor of n or more.
In section 8.3.4, a method is described to lower the CPU time required for repeated calcula-
tions of off-axis dose distributions in the beam shape optimization part, when more advanced
and more computation intensive dose algorithms are used. This method can be extended to
4D-planning.
8.4 Clinical issues for SBRT of liver metastases
8.4.1 Dose conformality and geographical tumor miss
To assess conformality of prescription isodoses to 3D PTV contours, the conformality index,
CI, was used, which is defined as the ratio between the volume enclosed by the prescription
isodose and the volume of the PTV. For CI values close to the ideal value of 1, the average
distance between the prescription isodose and the PTV surface is small. For the Cycle opti-
mized non-coplanar 3D-CRT plans (65% strategy) in chapter 4, the CI has an average value
of 1.26, while the CI for the clinical plans of these patients was on average 1.32. Timmerman
et al. recommend to keep the CI below 1.2, and use 1.4 as maximum limit [15]. Further de-
crease in CI of the Cycle 3D-CRT plans can be achieved by lowering the Cycle CI constraint
level, which will lead to a smaller distance between the PTV and the prescription isodose.
In chapter 3, it was shown that the difference between the minimum PTV dose and the
maximum dose at a distance of 2 cm outside the PTV is considerable higher for the optimized
non-coplanar plans compared to clinical treatment planning (Tab. 3.5). This suggests that the
dose gradient around the PTV is increased for computer optimized non-coplanar plans.
A study by Voroney et al. [16] showed that GTVs contoured on CT images are smaller
than GTVs contoured on MRI, and that the distance between the MRI-GTV and the CT-GTV
was larger than 5 mm for on average 19% of the GTV surface. Clinical GTV contouring
is based on CT images and potential deviations from MRI delineation are not explicitly ac-
counted for in the PTV margin. With the currently applied relatively high CI, plans might
be forgiving for (small) inaccuracies in PTV margin. For more conformal plans (i.e., with
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a lower CI) the probability of partial geographical tumor miss may increase. Higher dose
gradients just around the PTV, will increase the underdosage due to geographical tumor miss.
Currently, Erasmus MC is developing a new SBF, allowingMR-imaging in treatment position
to improve tumor delineation.
8.4.2 On-line re-planning
In the current treatment protocol, the planning CT-scan is used for contouring of the target
and OARs and for treatment planning. Prior to each treatment fraction, a CT is made to
determine the required isocenter shift for centering the CTV in the PTV[9]. In this daily im-
age guidance procedure, position changes and deformation of critical organs relative to the
planning scan are not considered, which might lead to higher OAR doses than planned, po-
tentially exceeding the applied planning constraints. Since the number of treatment fractions
is low, the random component of these inter-fraction changes in OAR position, orientation
and shape will not average out.
In an on-going study, OAR doses are retrospectively calculated for each fraction, using
the daily CT-scans and applied isocenter shifts. The OARs are contoured on these treatment
CT’s. Per OAR voxel the total delivered dose can be calculated by adding the dose contribu-
tions of the individual fractions. Since OARs might show intra-fraction deformation[13,17], a
challenge in this study is the correct co-registration of OAR voxels in each treatment fraction
to make proper calculation of the total dose delivered to each OAR voxel possible. Since the
biological effect of dose delivered in varying fractions is different from a dose delivered in
constant fractions, the addition of fraction doses has to be done in a biological way.
If significant deviations in realized OAR dose from planning dose are observed in this
retrospective study, the treatment protocol for future patients might be changed by including
daily dose calculations for treatment CT-scans. Unacceptable large calculated OAR doses due
to OAR displacements or deformations could then trigger canceling of the daily dose delivery.
For the more distant future, a system for daily re-planning based on the treatment CT could
then be developed. To avoid large increases in treatment time and patient discomfort, such a
system needs a fast re-planning method, i.e. within a couple of minutes.
8.5 Non-coplanar vs. coplanar liver SBRT
In chapters 3 and 6, treatment plans with optimized coplanar and non-coplanar beam setups
are compared for 3D-CRT and IMRT, respectively. For both treatment techniques it was
concluded that application of non-coplanar beams improves the treatment planning for SBRT
of liver tumors. However the observed increase in absolute DPTV, 99% due to a non-coplanar
setup differed considerably between both studies; 4.5% for the 3D-CRT plans (chapter 3),
and 23.2% for the IMRT plans (chapter 6). Possible explanations of this difference are:
• The optimization procedures applied in both studies were different on two points. In
chapter 3, for a fixed prescribed maximum tumor dose, the 3D-CRT plan with the high-
est possible minimum PTV dose within the applied planning constraints was generated.
In chapter 6, for each patient, the IMRT plan with the highest possible absolute PTV
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dose within the planning constraints was generated, while the ratio DPTV, min / Disoc
was kept constant at 65%. The second difference is that in chapter 3 the mean liver
dose was used as constraint, which was not used for the IMRT plans in chapter 6.
• Application of non-coplanar beam setups is much more advantageous for IMRT treat-
ments than for 3D-CRT treatments.
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Figure 8.1: Patient group mean differences for the PTV dose parameters DPTV, max, gEUD(-5),
gEUD(-20), and DPTV, 99% between optimized coplanar and non-coplanar beam setups for the
3D-CRT and IMRT plans of chapter 6.
In the planning procedure in chapter 6, Cycle is used to first generate 3D-CRT plans with
either an optimized coplanar or optimized non-coplanar beam setup. These set-ups are then
used to generate IMRT plans with the XIO treatment planning system. Separate comparisons
for 3D-CRT and IMRT in delivered PTV doses with coplanar and non-coplanar setups are
presented in Fig. 8.1 The dose increase in DPTV, 99% for the non-coplanar beam setups is
25.7% for the 3D-CRT plans and 23.2% for the IMRT plans.
Because of the small differences between 3D-CRT and IMRT plans seen in Fig. 8.1,
it is concluded that the observed relatively small differences in PTV dose between coplanar
and non-coplanar setups in chapter 3 (see above) result from the applied planning procedure
that differs from the approach in chapter 6. It seems that application of non-coplanar beams
instead of coplanar beams is more advantageous if the goal of the treatment planning proce-
dure is the generation of a plan with the maximally escalated PTV dose within the applied
planning constraints, than when the goal is to maximize the PTV dose homogeneity.
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Summary
Stereotactic radiotherapy is a treatment technique with a higher accuracy in 3D localization
and immobilization of the tumor than for conventional radiotherapy. For stereotactic radio-
therapy the dose is delivered in one or a small number of fractions with a high dose per
fraction, resulting in a much higher biological effective dose to the tumor. Therefore, ste-
reotactic radiotherapy is well suited for treatment of tumors that are highly insensitive to
radiation. For example, a dose delivered in 3 treatment fractions of 20 Gy, as often used for
lung tumors has the same biological effect as a dose of 150 Gy delivered in fractions of 2 Gy
(assuming α/β=10). Note that in the latter case 75 treatment fractions are needed, which is
generally considered too high.
Because of the low number of fractions with high doses, the advantage of a higher
inter-fraction repair for normal tissue than for tumor tissue is reduced for stereotactic radio-
therapy, potentially increasing the risk on late toxicity for the same anti-tumor effect. This
higher chance on late toxicity is counteracted by using more focused dose distributions, and
the increment in localization and immobilization precision, which allows for smaller target
volumes yielding smaller volumes of normal tissue receiving a high dose. The focused dose
distributions are characterized by a high degree of conformality of the prescription isodose to
the target volume, a high dose fall-off between target volume and normal tissue, and a min-
imized dose to the organs at risk. This thesis discusses several techniques for more focused
stereotactic irradiation of intra-cranial (chapter 2), and extra-cranial (liver) tumors (stereotac-
tic body radiotherapy, SBRT), chapters 3 to 7.
Small intra-cranial tumors (< 2 cm) are often treated with stereotactic arc therapy. With
this technique the dose is delivered to the patient with a number of non-coplanar arcs (i.e.
out of the patient’s axial plane), for which the gantry rotates during irradiation. The beam is
shaped with a cone collimator, resulting in a spherical volume that receives a high dose. In
chapter 2, a new method for increasing the conformality of the dose distribution to the tumor,
in case of a non-spherical tumor, by partial blocking of the cone collimator with the jaws
of the linear accelerator, is presented. Measurement of required input data for the treatment
planning system (TPS), for fields smaller than 2 cm, are described, together with correction
methods for increased electron disequilibrium and the smoothing effect of the detector. The
feasibility of the technique was proven by validation of TPS calculations with point dose
measurements on the central beam axis and measurements of off-axis dose distributions.
Moreover, the advantage of partial cone blocking in arc therapy for small intra-cranial lesions
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was shown in a planning study.
To maximize the conformality of a dose distribution to the target volume and the dose
fall-off between the target and healthy tissue, and to optimize sparing of organs at risk (OAR),
a SBRT treatment plan generally consists of many non-coplanar and coplanar beams. Many
beam combinations are possible, and finding the optimal set is not a trivial task. In clinical
practice, this step in the treatment planning process is performed by the technician, using
a manual trial-and-error procedure. Chapter 3 describes adaptations to an in-house devel-
oped beam direction and beam weight optimization algorithm (’Cycle’) for SBRT. Important
extensions of Cycle for SBRT were inclusion of beam shape optimization, and inclusion of
non-coplanar input beams. To study the impact of plan generation with Cycle, automatically
generated plans were compared to clinically applied plans, for a set of previously treated
patients with a liver tumor. The Cycle plans were optimized by maximizing the minimum
planning target volume (PTV) dose, while strictly adhering to the absolute prescribed tumor
center dose, and to the imposed OAR constraints. Both coplanar and non-coplanar Cycle
plans were compared with the clinical plan. It was demonstrated that automated beam direc-
tion optimization with the extended Cycle algorithm substantially improves the therapeutic
ratio for SBRT of liver patients, compared to the clinical plan. Furthermore, the Cycle opti-
mized non-coplanar plans were better than the optimized coplanar plans.
In stereotactic radiotherapy, the dose is prescribed to an isodose that closely surrounds
the PTV. For SBRT, often prescription isodoses of 65% or 80% are used. In chapter 4, Cycle
was used to generate liver SBRT plans, based on dose prescription at the surrounding 65%
isodose, or at the 80% isodose. It was concluded that on average the 65% strategy has a better
therapeutic ratio than the 80% strategy.
Radiobiological quantities, such as the gEUD(a), are intended as a measure of the bio-
logical effect resulting from an inhomogeneous OAR or target dose distribution. In chapter
5, treatment plans with a maximized PTV gEUD(a) (without limitations on other PTV dose
parameters) are generated with Cycle, and compared with the strategies using a 65% or 80%
prescription isodose. All plans had to strictly comply with the imposed OAR hard constraints.
It was demonstrated that on average, gEUD(a) optimization is superior to conventional strate-
gies with a 65% or 80% isodose that closely surrounds the PTV.
In chapter 6, optimized non-coplanar and coplanar beam set-ups for 3D-CRT plans gen-
erated with Cycle, are used as input for an external IMRT optimization system (XiO, CMS)
to generate optimized IMRT plans. For both the generation of the coplanar and non-coplanar
Cycle 3D-CRT plans, and the IMRT plans, the same optimization procedure was used; max-
imization of the total PTV dose without violation of the OAR constraints. The coplanar
and non-coplanar IMRT plans are compared with an IMRT plan with a non-optimized, 11
equi-angular, coplanar beam set-up. It was concluded that the IMRT plans for the optimized,
non-coplanar beam set-ups have substantially higher doses delivered to the PTV than both
the IMRT plans based on optimized coplanar beam orientations, and IMRT plans generated
for the equi-angular set-up. On average, IMRT plans with an optimized coplanar beam set-up
had a slightly higher PTV dose than IMRT plans with the 11 equi-angular beam set-up.
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Clinical introduction of improved treatment technology, e.g. daily 4D-CT image guid-
ance for SBRT of liver tumors may allow the use of smaller CTV-PTV margins. In chapter
7, Cycle was used to generate treatment plans with different CTV-PTV margins. These plans
were compared with a Cycle plan with the clinical CTV-PTV margin. It was concluded that
due to decreases in CTV-PTV margin, a considerable improvement in therapeutic ratio can
be achieved.

Samenvatting
Het onderwerp van dit proefschrift is behandelplannen voor stereotactische radiotherapie.
Stereotactische radiotherapie is een behandelingstechniek voor het bestralen van tumoren
met megavolt fotonen bundels. Deze bestralingstechniek onderscheidt zich van conventionele
radiotherapie door een verbeterde geometrische nauwkeurigheid bij zowel de lokalisatie als
bij het toedienen van de dosis aan de tumor.
Een tweede onderscheid is dat de stralingsdosis wordt toegediend in een klein aantal
fracties met een hoge dosis per fractie. Dit heeft een verhoogde biologische schade aan het
tumorweefsel en een hogere kans op tumor controle tot gevolg, met name voor tumoren die
relatief ongevoelig voor ioniserende straling zijn. Bijvoorbeeld, een dosis van 60 Gy die in
3 fracties van 20 Gy wordt toegediend, heeft hetzelfde biologische effect als een totale dosis
van 150 Gy toegediend in fracties van 2 Gy. In het laatste geval zijn 75 fracties nodig, wat
onacceptabel hoog is.
Omdat het toedienen van de dosis in een klein aantal fracties ook een relatief hogere
biologische schade aan gezond weefsel geeft, is de mate van focussering van de dosis op
de tumor uitermate belangrijk. Belangrijke eigenschappen van een dosis verdeling zijn: de
mate waarin de isodose, waarop de dosis wordt voorgeschreven, conform met het doelvolume
loopt, een hoge dosis gradie¨nt tussen het doelvolume en het gezonde weefsel en het voldoen
aan de dosis limieten voor de verschillende kritieke organen. In dit proefschrift worden een
aantal technische verbeteringen voorgesteld en onderzocht voor meer gefocusseerde dosis
verdelingen voor stereotactische radiotherapie voor intra-craniale tumoren, hoofdstuk 2, en
voor extra-craniale tumoren, hoofdstuk 3-7.
Voor stereotactische radiotherapie van kleine intra-craniale tumoren (< 2 cm) wordt
vaak arc therapie gebruikt waarbij de gantry van de lineaire versneller roteert tijdens het stra-
len. Vanwege de kegelvormige collimator is de bundel cirkelvormig. Voor tumoren die niet
bolvormig zijn zou de dosisverdeling meer conform aan de tumor gemaakt kunnen worden
als de bundelvorm aangepast zou kunnen worden door middel van het afblokken van de cir-
kelvormige velden met de collimator blokken van de lineaire versneller. Metingen van de
invoerdata voor het treatment planning systeem (TPS), en de correcties voor gebrek aan elek-
tronen evenwicht en het uitsmeer effect ten gevolge van de afmeting van het detectievolume
van de detector zijn beschreven. De beschreven methode is gevalideerd door vergelijking
van TPS berekeningen met metingen. Voor twee patie¨nten werd retrospectief een nieuwe
behandelplan gemaakt. Beide plannen waren een verbetering ten opzichte van het oude plan,
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waarbij geen afblokking van het veld was gebruikt.
In hoofdstuk 3 wordt de aanpassing van een bestaand computer algorithme voor bun-
del richting selectie en optimalisatie beschreven om het toepasbaar te maken voor treatment
planning voor stereotactische behandeling van levertumoren (stereotactic body radiotherapy,
SBRT). De aanpassingen bestonden uit het toevoegen van bundels die niet in het axiale vlak
van de patie¨nt liggen (non-coplanaire bundels) en van optimalisatie van de bundelvorm. Kli-
nisch werden bundelrichting en bundelvorm gekozen door een laborant op basis van ervaring.
Vanwege het grote aantal vrijheidsgraden is de kans op een suboptimaal planning resultaat
groot. Met het aangepaste algoritme is aangetoond dat de behandelplannen, waarbij bundel-
hoek optimalisatie is toegepast, beter zijn dan de plannen die klinisch worden gebruikt voor
3D-CRT. Daarnaast is aangetoond dat de plannen met bundelhoek optimalisatie, waarbij ook
non-coplanaire bundels mogen worden geselecteerd, beter zijn dan plannen waarbij alleen
coplanaire bundels mogen worden geselecteerd.
De dosis voor het planning target volume (PTV) wordt voorgeschreven op de isodose
die kort rondom het doelvolume loopt. Sommige instituten gebruiken hiervoor de isodose
met 80% van de iso-centrum dosis, terwijl andere instituten hiervoor de 65% isodose gebrui-
ken. In hoofdstuk 4 wordt een vergelijking tussen beide strategiee¨n gemaakt. Daarvoor zijn
met Cycle plannen gemaakt met zowel de 65% als de 80% strategie. Het blijkt dat de plan-
nen voor de 65% strategie gemiddeld beter zijn dan die voor de 80% strategie. Grootheden
als de gEUD(a) worden gebruikt als maat voor het totale radiobiologische effect van een do-
sisverdeling in een structuur (kritiek orgaan of doelvolume). In hoofdstuk 5 zijn met Cycle
plannen gegenereerd waarbij de gEUD van de PTV werd geoptimaliseerd. Deze plannen zijn
vergeleken met de plannen van de 80% en de 65% strategie. Het bleek dat de gEUD strategie
in betere plannen resulteerde dan de 80% en de 65% strategie.
In hoofdstuk 6 is de combinatie van IMRT met bundelhoek optimalisatie onderzocht.
Hiervoor zijn met Cycle voor elke patie¨nt twee 3D-CRT plannen gegenereerd; een met een
coplanaire en een met een non-coplanaire bundel set-up. De bundelrichtingen van deze plan-
nen zijn ingevoerd in het XIO planning systeem. Met dit systeem is vervolgens een geopti-
maliseerd IMRT plan gemaakt. Ook is er voor een bundel set-up met 11 coplanaire bundels
met een vaste hoekafstand tussen de bundels een geoptimaliseerd IMRT plan gemaakt. Uit
de vergelijking tussen de drie verschillende IMRT plannen bleek, dat de IMRT plannen met
een non-coplanaire bundel set-up veel beter waren dan die met een coplanaire bundel set-up.
Ook de IMRT plannen met een geoptimaliseerde coplanaire bundel set-up waren gemiddeld
beter dan de niet geoptimaliseerde coplanaire plannen.
Klinische introductie van meer geavanceerde technologie, bijvoorbeeld 4D-CT, kan lei-
den tot kleinere CTV-PTV marges en dus kleinere PTVs. In hoofdstuk 7 zijn voor verschil-
lende CTV-PTV marges met Cycle voor SBRT van lever tumoren 3D-CRT plannen gemaakt,
welke zijn vergeleken met het Cycle plan met de klinische CTV-PTV marge. Deze vergelij-
king toont aan, dat door verkleining van de CTV-PTV marge een aanzienlijke toename in de
therapeutische ratio behaald kan worden.
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